Abstract
The power of ribosomes has increasingly been harnessed for the synthesis and selection of molecular libraries. Technologies such as phage display, yeast display, and mRNA display effectively couple genotype to phenotype for the molecular evolution of high affinity epitopes for many therapeutic targets. Genetic code expansion is central to the success of these technologies, allowing researchers to surpass the intrinsic capabilities of the ribosome and access new, genetically encoded materials for these selections. Here we review techniques for the chemical expansion of genetically-encoded libraries, their abilities and limits, and opportunities for further development. Importantly, we also discuss methods and metrics used to assess the efficiency of modification and library diversity with these new techniques.
Keywords: genetically encoded libraries, peptide libraries, display technologies, quality control metrics, chemical modification, unnatural amino acids
Graphical Abstract
Introduction.
A number of new ligand selection technologies are increasingly being used in drug and probe discovery efforts. Technologies such as DNA encoded libraries (DELs),1 mRNA display,2 and phage display3 significantly reduce the instrumentation costs and time relative to traditional high-throughput screening (HTS),4–6 while also increasing the frequency of success against some of the most challenging therapeutic targets.7–13 These techniques, which rely on genetic barcodes to deconvolute hits from complex mixtures, allow large compound libraries (~109-1013 compounds versus ~104-106 compounds for HTS) to be assayed in one pot and have been successfully used to identify high affinity ligands for numerous disease-implicated protein targets.7,14–23 Indeed, many of these methods are quickly finding broad application in drug discovery efforts in both academia and industry.24–28
Genetically encoded libraries (GELs), which include mRNA display, phage display, yeast and cell surface display libraries, as well as intracellular SICLOPPS29,30 and plasmid-encoded libraries, are particularly powerful. GELs are unified as selection methods in that they depend on ribosomes for library synthesis and are inherently highly peptidic as a result. Through the power of ribosomes, GELs can be synthesized rapidly, in high fidelity, and with relatively minimal effort, and present some of the largest libraries (up to 1013 molecules) prepared to date. In contrast to DELs and small molecule libraries, GELs can be synthesized directly from their genetic barcodes, allowing for multiple, iterative rounds of GEL screening to be easily performed for the enrichment of high affinity ligands. Additionally, GEL compounds are typically larger, which can aid in allowing them to better disrupt protein-protein interactions due to their increased surface area.13,18,22,31–35 Although there are still limitations, most notably in cell permeability and chemical space, the unique benefits of GELs have not gone unnoticed and many major pharmaceutical companies have partnered with or imported GEL-based ligand selection programs for drug discovery campaigns.36–42
The power of GELs in ligand discovery has inspired numerous efforts to expand GELs beyond their innately peptidic chemical space and enable GEL-based screening with non-natural or small molecule-like functionalities. Such chemical functionality that goes beyond the natural proteinogenic amino acids could further enhance the rates of success in affinity selections while also improving drug-like properties, permeability, and stability of hit compounds.43–47 To this end, new diversity elements or building blocks have been incorporated into GELs either co-translationally, by hijacking steps in the ribosomal assembly process, or post-translationally, by modifying the ribosomal products of translation. Cell-free translation systems, orthogonal tRNA synthetases, and engineered ribozymes have all been recruited or developed to expand the chemical diversity that can be filed through the ribosome via genetic code reprogramming or expansion.48,49 Meanwhile, chemical and enzymatic transformations can introduce modifications, such as multiple macrocyclizations50–52 or backbone modifications53,54 that otherwise prove challenging to ribosomal incorporation. Together, an array of more than 300 non-canonical groups can now be incorporated into GELs of various kinds and the libraries that can be accessed look less like the simple peptides of early days and more akin to the natural products deployed by many microbes. Such methods are providing a promising new array of GEL libraries for next-generation targets.
In this review, we attempt to comprehensively and concisely summarize advances in expanding GEL diversity, through both translational and post-translational means. We strive to provide an organized presentation of methods used to expand GEL chemical diversity, key barriers to their implementation, and a catalog of the chemical diversity that can be accessed; we eschew exhaustive descriptions of the selections or binders that result from using these diversified GELs. Importantly, with respect to post-translational diversification, this is not a review of biologically compatible chemistry that might be used to modify GELs, but only of chemistries that have been site-specifically validated on GEL members, as several hurdles must be passed before a given reaction can be reliably employed with GELs. These hurdles include: installation of a diversity element on 1) a translated peptide, 2) a displayed molecule, 3) a displayed library, and 4) a ligand identified from a selection. The hurdles to diversifying GELs depend on the selection system in use, and diversification methods are presented with this consideration in mind. Additionally, the proliferation of methods to expand GEL chemical diversity has required concomitant advances in techniques to assess library quality post-modification. Consequently, we also discuss important quality control metrics and provide a summary of the assays that have been used to measure them. Thus, this paper is presented in three distinct sections: section 1 discusses quality control metrics to consider when diversifying GELs and accompanying assays to quantify them, section 2 summarizes methods to expand GEL diversity during translation and their documented substrate scopes, and section 3 summarizes approaches to post-translationally expand GEL diversity. We hope the focused scope of this review will prove a practical guide for those who are looking to incorporate new diversity elements into GELs for selection purposes.
Quality Control and Diversity Metrics.
Quality control is arguably the most important part of a GEL, as poorly compatible diversification strategies may result in library degradation, false positive enrichment, and/or failed selections. For a diversity element to be successfully enriched in selections, it must be sufficiently and specifically incorporated and not interfere with the genetic material by which library members are propagated and identified. Thus, it is important to consider the established metrics through which incorporation can be measured and how they might be assessed to assure high quality libraries for use in benchtop selection campaigns (Figure 1). This section first defines these quality control metrics, then subsequently recounts assays that have been used to quantify them.
Figure 1.
Quality control metrics and accompanying assays to assess GEL diversification strategies. A) Schematic of a chemically diversified GEL selection with applicable quality control metrics (yellow numbers) at each step. B) Common methods to assess GEL quality control metrics and their direct uses.
Library Metrics
Library Size & Chemical Space.
Two metrics used to define all libraries, chemical or genetic, are library size and chemical space (Figure 1A). Both parameters are largely theoretical but are essential in evaluating the utility of a given library. Library size refers to the theoretical number of unique members that could exist in a library. For a GEL, this number is calculated by exponentially multiplying the number of randomized codons by the number of amino acids allowed per codon. Library size is an essential consideration during selection planning because a larger library often correlates with a higher degree of success. Additionally, it may prove beneficial to ensure that libraries present more molecules than their theoretical library size in a naïve selection so that every potential sequence iteration is accounted for. Chemical space should also be considered when designing a library. For small molecule libraries like those used in high throughput screening (HTS), physicochemical properties such as molecular weight, AlogP, number of hydrogen bond donors/acceptors, and polar surface area, are often used to estimate chemical space.55,56 Since GELs are inherently peptidic, this parameter is more commonly estimated by assessing the distribution of sequence counts throughout a library to establish that no particular sequences are overrepresented and that amino acids are uniformly accounted for. However, unnatural amino acids (UAAs) and other diversity elements can dramatically impact chemical space and even add new dimensions, such as ring size and topology in the case of cyclic peptide libraries. Ultimately, the chemical space of modified GELs is an important indicator of their broader utility.
Metrics for Translational Diversification.
To incorporate new functionalities with translational machinery, UAAs and other building blocks must first be loaded onto tRNAs, and then accepted by the ribosome. Thus, tRNA acylation efficiency and translation efficiency are important metrics used to assess new methods for introducing diversity elements via ribosomal translation (Figure 1A). tRNA acylation efficiency refers to the percent of tRNA that is properly acylated with the desired UAA, while translation efficiency is based on the ability of the translation system, in vitro or in vivo, to incorporate a given UAA into the sequence of a displayed peptide or protein at the desired codon. Several different assays have been developed to measure both metrics, each of which are discussed in further detail below.
Metrics for Post-Translational Diversification.
Chemical and enzymatic transformations can also be performed on translated libraries to introduce diversity. Some of the metrics used to assess post-translational modifications are similar to those employed in solution phase organic synthesis, such as percent yield and regioselectivity (Figure 1A). As might be expected, yield is defined as the percentage of chemical handles in a library that are successfully altered by a post-translational modification (PTM). Percent yield is both the most important and most difficult metric to assess; the number of methods used to measure percent yield is almost as varied as the number of chemistries used to modify GELs. There is no established acceptable value for this metric and yields vary greatly depending on the PTM. Generally speaking, yields within an order of magnitude of the total library size (i.e. ≥10%) are commonly seen in the literature,53,57–59 but yields as high as 90% modification have been reported.60 Regioselectivity refers to selectivity of a modification for its intended site, but more practically can be thought of as an extent of off-target modifications or cross-reactivity with other components of the display system, such as surface proteins or other library members.
Another critical metric for post-translationally modified GELs is genetic viability (Figure 1A), or the remaining integrity of genetically encoded material after a PTM is performed. For in vitro display systems this predominantly relates to the ability of DNA to be amplified, sequenced, and/or propagated in a selection round. For in vivo display systems, such as phage display, one must additionally consider retention of infectivity or cellular growth after library modification. Acceptable amounts of genetic loss due to PTM vary depending on the library size. Most reported modifications attempt to create mild reaction conditions that keep library viability as high as possible, but PTMs have certainly been reported that reduce library viability by an order of magnitude (~90% decrease). For example, the well-known phage bicyclization strategy developed by the Heinis group significantly decreases phage viability upon addition of micromolar concentrations of cyclizing reagent, presumably due to the cross-linking of lysine residues between phage particles, leaving them noninfective.50,61 Despite this loss however, multiple selection campaigns have successfully been performed with this PTM.14,16,17,19 Indeed, since GELs can be as large as 1013 molecules, substantial losses in genetic viability may still be tolerable as long as the remaining library members still encompass theoretical library diversity.
General Definitions & System-Specific Considerations.
Several other metrics are important for both translationally and post-translationally diversified GELs. Sequence bias (Figure 1A), or the change in sequence distribution over rounds of selection, is an essential metric for both strategies as a diversity element may cause artificial enrichment if its incorporation is favored in proximity to certain amino acids. Diversity elements that are incorporated at the amber codon during translation may be subject to additional sequence bias, as sequences containing nonsense codons can be outgrown by those with only sense codons. A degree of sequence bias may also be inherent to certain display systems, such as in phage display, where sequences that aid in infectivity could be enriched for, or in mRNA display, where PCR bias may occur, during amplification between selection rounds. Additionally, display valency (Figure 1A), which refers to the number of peptide or protein “phenotypes” expressed per “genotype”, can be variable in phage and cellular display systems and is relevant when calculating percent yield. Importantly, multivalent display can facilitate cross-reactivity between displayed peptides due to proximity and impact library quality. For phage display one must also consider where to express the library on the phage particle (i.e. which coat protein), which will dictate display valency, as well as several other parameters.
Quality Control
Library Size & Chemical Diversity.
Besides calculating the maximum number of unique library members to estimate theoretical library size, measurements are also usually taken to quantify the number of displayed molecules in a library during a given selection round (Figure 1B). For in vitro selection techniques like mRNA display, the number of peptide-mRNA fusions produced in translation can be quantified through amplification in qPCR and comparison to a standard curve. For phage display, plaque forming assays are generally performed to calculate viral titer, a quantitative measurement of the biological activity of phage virions. Plaque forming units (PFU) are the most common measurement of phage concentration, but quantification of phage particles in solution is also made possible via absorption spectrophotometry given length of viral DNA. Transformation efficiency of plasmid libraries in cellular display systems can be routinely calculated via colony forming assays. These assays only quantify the portion of a library with viable genetic material and do not give a direct indication of whether a library member is successfully displayed; secondary assays are often performed to ensure proper library expression.
Because GELs are innately peptidic and synthesized de novo by ribosomes, they are not frequently assayed for their chemical diversity. The chemical diversity of macrocyclic DNA encoded libraries (DELs), however, has been characterized according to basic physicochemical properties, including those associated with Lipinski’s rule of 5 and by Veber descriptors,62,63 as well as lowest energy 3D conformation.64 These properties have then been compared to published guidelines for oral macrocyclic drugs (i.e. Kihlberg parameters),65 or to predict solvation energy and the likelihood of cell permeability.64 This characterization however is less frequently done with GELs; instead, the initial chemical diversity of a library is qualitatively evaluated after its construction and/or transformation via next generation or deep sequencing (Figure 1B). The library is typically analyzed for number and distribution of sequence counts, as the overall number of unique counts verifies library size while sequence distribution serves as an indicator for good chemical diversity. Inspection of a library for sufficient sequence coverage, minimal sequence bias, and minimal truncates is a critical QC checkpoint before subsequent library expression and selections.
tRNA Aminoacylation & Translation Efficiency.
There are several different methods for measuring tRNA aminoacylation that are required for introducing diversity elements via translational diversification (Figure 1B). (1) The standard ATP/PPi exchange assay has been used extensively to confirm UAA activation by aaRSs and adenylation domains66–70, however it cannot inform on tRNA acylation. (2) In the [α32P]-AMP radioisotope assay, the tRNA is labeled with [α32P]-AMP at the 3’ end, then acylated, derivatized, and cleaved; acylation is measured by TLC separation and autoradiography.71 (3) As long as the UAA contains an α-amino group, reaction of the free amino group with a biotinylating agent, such as sulfosuccinimidyl-D-biotin, allows for separation of acylated from non-acylated tRNA via a gel-shift assay or by MALDI-TOF.48 In the case of MALDI-TOF, the UAA is derivatized and cleaved from the tRNA by nuclease P1 before analysis.72,73 (4) Lastly, Suga has developed a microhelix assay, which is currently one of the most robust and versatile methods to assess tRNA aminoacylation via ribozymes. This assay makes use of an RNA microhelix that mimics the acceptor arm of the tRNA. Because the microhelix is small relative to full length tRNA, it can be directly run on an acid PAGE gel without need for prior derivatization to determine the degree of acylation. The microhelix assay has been used extensively to optimize conditions for acylation by Flexizyme (Fx) and is currently the only reported assay used to measure percent acylation of a UAA lacking an α-amino group.48,74 In general, an acylation efficiency above 10% is accepted as sufficient for further testing in translation efficiency.48
Translation efficiency of a UAA is measured slightly differently depending on whether translation is done in vitro or in vivo. In vitro translation efficiency has commonly been measured by equipping a C-terminal tag, such as FLAG or 6x-His, with a radioisotope-labeled amino acid (e.g. 14C-Asp, 35S-Met, or 3H-His) to a model peptide (Figure 1B). This peptide is then separately translated with and without the UAA-charged tRNA; translated peptides are then affinity purified and run on a tricine SDS-PAGE gel.75 UAA translation efficiency is calculated relative to translation of the peptide with canonical amino acids based on autoradiography. The identity of the UAA-containing peptide should also be confirmed via MALDI-MS (Figure 1B) to ensure little or no background incorporation of canonical amino acids.48,74,76,77 In vivo translation efficiency on the other hand is measured in several different ways depending on the display system. PFU of phage display libraries are often analyzed in the presence or absence of a desired UAA, and fold enrichment in plaque formation is calculated to estimate UAA incorporation.78,79 Alternatively, in phage, a successfully incorporated UAA can be recovered and quantified via capture assays as discussed below.80,81 Other in vivo libraries that are not exposed on the cell surface, such as in SICLOPPS and plasmid-encoded libraries, rely on cell lysis and library capture for analysis via MALDI or SDS-PAGE.15,35 In most cases, efficiency is quantitatively assessed by comparing the amount of peptide(s) from canonical translation to that from translation with the UAA.15,35,82,83 Translation efficiencies as low as 12%84 and as high as 164%75 have been reported in mRNA display. The Suga group uses 10% efficiency84 or 0.1 uM translated peptide85 as sufficient for use in selection while the Szostak group uses 25% efficiency76 as sufficient, however no cutoffs for in vivo GELs have been reported.
Percent Yield of PTMs.
Percent yield is likely the most important metric for assessing the utility of PTM strategies for GELs. The methods used to assess percent yield of a PTM are fundamentally similar to those used in assessing translation efficiency of a UAA in that they often involve preliminary isolation of molecules containing the diversity element followed by their subsequent quantitative detection. Yet, the size and complexity of many GELs makes measuring percent yield non-trivial. As such, there are several different tactics that have been used to quantify the yield of a given modification, including: 1) capture assays, 2) subtractive capture assays, 3) MS-based methods, and 4) positive control selections. Each strategy has its benefits and drawbacks. It is important to note that many times, due to the large size of GELs, these strategies are employed in model systems only and results are extrapolated to future libraries, although there are select examples of PTM validation on a library during the course of a selection campaign.
Capture assays involve the direct, quantitative reaction of a newly introduced functional group with an orthogonal detection reagent (capture reagent). The capture then allows for affinity or electrophoretic separation from unreacted materials and quantitation by fluorescence, radioactivity, ELISA, qPCR, or other methods depending on the type of GEL being explored (Figure 1B). A representative example of the capture assay is the biotinylation of a library followed by ELISA with a streptavidin-HRP antibody,86 which can then be compared to a standard curve for quantitation relative to wild-type, unreacted phage. Biotinylation can also be followed with SDS-PAGE and western blotting,87 or streptavidin pulldown and measurement of either the bound53,58,59,88 or free86,89 (supernatant) fraction to calculate yield from an unreacted control. When necessary, this kind of approach can be extended by additional reactions, such as in the case of a phage library where chemically installed boronic acid handles were validated via reaction with a fluorophore-labeled semicarbazide and SDS-PAGE analysis.90 Alternatively, if a diversity element is not successfully installed on all library members, a subtractive capture can be used to sequester the unmodified portion of the library. In this case, the unreacted remainder of the library is measured to indirectly calculate the percent yield of a given reaction. Both biotin and FLAG tags have been used as chaser reagents to measure yield in indirect pulldown assays.53,59,88,90,91 Importantly, for libraries presenting more than one reactive handle, as is the case with poly-cysteine bicyclization strategies50 or orthogonal click-based intracyclization,52 two distinct PTM chasers, each with one component of the reaction (i.e. azide/alkyne, thiol/alkyl halide) have been strategically used to measure the unreacted, mono-reacted, or bis-addition products in comparison to cyclized counterparts.91,92
A number of variations on the capture assay have also employed detection reagents such that the PTM under investigation impacts reagent recovery. For example, Roberts and coworkers placed a 35S methionine downstream of a base-labile ester linkage in an mRNA display library while developing a method for post-translational library cyclization; if cyclization chemistry was unsuccessful, the radiolabel would be lost on workup.93 Alternatively, proteases have been used in tandem with reporter assays to assess the PTM of various GELs.36,54,94 For instance, van der Donk et al. used a 6x-His tag to monitor lanthipeptide formation in a phage display library; properly formed lanthipeptides could be selectively cleaved with NisP, leading to a decrease in His tag recovery as determined by densitometric analysis.94 Similarly, GluC has been used to probe for PTM of mRNA display libraries with the enzyme PaaA by cleaving unmodified peptides from a biotin tag.54 Given that GELs are mostly peptidic, proteases can be very powerful in quantifying percent yield of GEL PTMs.
Mass spectrometry (MS) has been used quite extensively to assess yields of PTM chemistries (Figure 1B). Because MS is not strictly quantitative, yields determined in this manner are typically relative yields and require some degree of benchmarking. Additionally, the small quantity of each peptide member in most display libraries means that a separate scale-up step is required for MS characterization of single display genes and results are then extrapolated to the library as a whole. Thus, MS-based strategies are used on fully displayed peptides after separation from their genetic encoding element or else with model peptide precursors that are not yet displayed. Several strategies have been used to cleave or separate peptide “phenotypes” from their genotypes, including equipment of model display peptides with TEV cleavage sites in mRNA display,95 reduction of disulfide linkers on the cell surface in yeast display,94 and cell lysis followed by affinity purification for other in vivo display methods such as plasmid-encoded libraries and split-intein ligation.18,96 Notably, for phage display, direct MS of the pIII coat protein on whole phage cannot be done because its copy number is too low (~5 copies/phage) relative to the abundance of other coat proteins like pVIII (~103 copies/phage). Thus, PTM of purified coat proteins and subsequent MS has been used as a surrogate for chemistry on whole phage particles.50,60 For chemistry where no change in mass occurs, it is possible to perform a subtractive capture assay with a capture reagent discernable by MS.52 In several instances, simple MS validation on translated but non-displayed peptides have also been reported as an initial PTM validation step.51,97 Although individual peptides can be easily validated by MS, the percent yield of PTMs on small libraries of translated peptides has also been estimated by fitting MALDI-MS data curves to a Gaussian distribution and calculating the curve area for percent conversion.98
Finally, in many cases, a positive control selection has been used as a surrogate for yield or else paired with other methods to provide definitive proof of modification. In such selections, the experiment is designed such that enrichment or sequence convergence is only possible if the PTM is successfully performed. For example, in the enzymatic phosphorylation of a phage display library with various kinases, enriched sequences converged on the recognition motifs of each kinase after multiple “selection” rounds.99,100 Alternatively, chemically equipping a library with a specific binding epitope should selectively enrich for chemically modified sequences when selecting against the complementary protein. This has been done with a biotin PTM and streptavidin selection, mannose PTM and concanavalin A selection, sulfonamide PTM and carbonic anhydrase selection,101 and EGFR peptide PTM and EGFR selection.86 If the PTM displays unique biological activity, as is the case for lanthipeptides, testing for antibiotic activity after display can act as another positive control.94
Overall, there are many approaches to calculating percent yield for a PTM, and while direct protocols can be case-specific, general tactics can be observed. Notably, many of these assays can be conducted in a pulse-chase approach over multiple time points to also gain insight into the reaction rate of a PTM on a given library, a metric which is rarely thoroughly studied, but worth considering.
PTM Regioselectivity.
Ensuring that a PTM has desired regioselectivity is important for a library’s success in selections, as off-target modifications could result in unintended library structures or cross-reactivity between library members, which in turn could affect genetic viability. Heinis’ phage display bicyclization strategy50 for example, while proven in its utility, suffered from some side-reactivity with methionine and lysine side chains and N-terminal free amines when using a cysteine-free M13 phage variant.102 Fortunately, regioselectivity can often be simultaneously assessed while determining PTM percent yield. Employing fluorescent reporters to measure yield via SDS-PAGE and in-gel imaging (Figure 1B) can also indicate site specificity if done alongside controls lacking the reactive handle, as fluorescence should only appear on the chemically amenable fusions.52,90,103,104 For in vivo display systems, observed fluorescence in negative control gel bands can potentially be sourced back to the protein(s) undergoing unexpected modification. Fluorescence reporting has also been used in synergy with affinity tag-containing libraries based on the principle that affinity tag and fluorescence detection should only occur at the same site if a PTM is regioselective.92,103 For libraries with more than one reactive handle, nuclease digestion and SDS-PAGE analysis has been used to identify the number of different products per PTM.105 Furthermore, peptides that are sequestered to assess PTM percent yield via MS, as described above, have sometimes been further analyzed by tandem MS to deduce regioselectivity.18,94 It is also possible to overexpress peptides on a display molecule to achieve appropriate concentrations for LC-MS/MS analysis, as was done for PTM of a special high copy phage vector that expressed increased peptides per phage particle.103 Despite these isolated examples, it can be challenging to discern regioselectivity by MS, even on single molecules.
Notably, Derda and coworkers have developed a phage display regioselectivity assay called a “blue/white” screen (Figure 1B). In this assay, chemically amenable phage carry a reporter gene that enables blue plaque formation after PTM, whereas unreactive control phage form clear plaques. A PTM is performed on a mixture of both phage types, and after isolation of modified phage, libraries are spotted on bacterial lawns and the number of blue versus white plaques that form are compared. This assay has been used to assess the regioselectivity of numerous phage display PTMs developed in their lab.53,59,88,91
Genetic Viability.
It is critical to validate that libraries retain genetic viability after PTM. Because this metric is only concerned with the genotypic portion of a displayed molecule, the assays to measure genetic viability are similar to those used to assess initial library size upon translation, and largely focus on amplification and degradation of genetic material. In regard to amplification, this entails measuring the qPCR cycles,95 or colony and PFU (Figure 1B),50,53,59,87,88,103,106 generated by displayed molecules in comparison to non-treated or solvent only controls to investigate how amplification differs after subjection to reaction conditions. If the genetic material is directly accessible, it is also possible to visualize the extent of its degradation via SDS or urea PAGE.52,105 Finally, subjecting a model display gene to multiple rounds of chemistry can reveal whether genetic material remains viable in a mock selection environment.107
Sequence Bias.
The extent of sequence bias resulting from library PTM can be visualized via the same methods used to assess initial library diversity and chemical space, through next generation and deep sequencing (Figure 1B). While powerful techniques, sequencing results may still be skewed by PCR bias when amplifying low copy number vectors or templates. Some studies exist that investigate the extent of sequence bias inherent to phage display,108,109 but there are few reports that interrogate this phenomenon in other display systems. Sometimes, researchers will report the number of unique sequences in their naïve library as a percentage of theoretical library size and use this value (usually at least >30%,94 up to 99%18) as an indicator of good sequence distribution. Still, this can only be done with a naïve library as it cannot indicate the extent of sequence bias after any selection rounds. There are even fewer attempts to deliberately evaluate PTM-induced sequence bias, but a recent report by the Derda group revealed that two specific PTMs involving N-terminal oxime ligation and cysteine thiol alkylation on phage display libraries returned sequences that were distinctly lacking in Phe and Ser residues.110 While the exact mechanism behind this bias remains unclear, the authors more readily attribute the bias to processing defects of the library rather than the PTM itself. Importantly, they also observed different residue biases depending on where the naïve library was expressed on pIII, revealing some of the inherent bias that may occur when using phage display versus other display systems. Auspiciously, emulsion amplification111 has been used to retain recovery of slow-growing phage clones with sequences that would otherwise be lost to their rapidly growing counterparts during amplification.
Display Valency.
Measuring display valency is of concern for in vivo display techniques that express libraries on virion or cell surfaces. Known valency is required to accurately calculate percent yield of a PTM, but it is also useful for ensuring that viable virions or cells are successfully displaying a given library. The most widely used phage display system, which utilizes M13 filamentous bacteriophage, expresses libraries on the N-terminus of the pIII coat protein for a maximum display valency of five library members for every phage particle.112 However, depending on the size of the library insert, wild-type pIII may be preferentially incorporated, resulting in a majority of wild-type, non-displayed phage particles and only a small percentage of monovalent phage particles expressing the desired library.113 This inconsistency in display valency can confound characterization of PTMs on phage displayed libraries. To combat expression issues, a phagemid system employing helper phage can be used to achieve consistent monovalent display.61,94 Successful cell-surface display has been quantified by equipping the displayed peptide with a recognition domain92 or affinity tag18 for subsequent immunostaining and flow cytometry analysis (Figure 1B). Median fluorescent values can be compared with a standard curve to estimate the number of peptides displayed per cell.92 The capture assays used to measure percent yield can be also run in tandem with unreactive controls to measure the extent of library expression. Additionally, the Derda group has used binomial statistics to link reaction yields of a PTM with unreactive or non-expressive M13 phage and estimate the number of modified peptide copies displayed on each particle.53
Exploiting the Promiscuity of Ribosomal Translation.
The ribosomal translation machinery is remarkably flexible and has proven to be one of the most powerful tools for expanding the chemical diversity of GELs. The primary hurdle to exploiting this flexibility is the introduction of a UAA or other acyl group of choice onto the chosen tRNA. As detailed below, four primary methods have been employed to alter and control tRNA loading and are discussed in greater detail below: 1) chemical aminoacylation, 2) native tRNA synthetase/tRNA pairs, 3) ribozyme-mediated acylation, and 4) orthogonal tRNA synthetase/tRNA pairs. Of these methods, only orthogonal tRNA synthetases are currently compatible with in vivo GELs, such as SICLOPPS or phage display. The other three methods take advantage of the extreme control afforded by in vitro transcription/translation cocktails and have thus been employed extensively in mRNA and ribosome display. Many of these methods were first used for genetic code reprogramming, where codon boxes are hijacked, such that a UAA(s) is introduced by replacing a natural amino acid(s). Each technology has its advantage when it comes to introducing new UAAs into the available pool of building blocks for a library but each method of genetic code reprogramming, is limited to reprogramming only the 20 available natural amino acids. However, rapid advances, such as splitting codon boxes and four-base codons, have provided additional control and now allow substantial genetic code expansion, such that the 20 natural amino acids can be maintained or even extensively reprogrammed, while one or more unnaturals are simultaneously introduced.114 Advantages and disadvantages of reprogramming and expansion methods are discussed below, as well as a review of the UAAs that have been incorporated into translated peptides.
Chemical and Chemoenzymatic Acylation of tRNAs
Chemoenzymatic preparation of tRNAs has been used extensively to load tRNAs with UAAs for incorporation into proteins, antibodies, peptides, and aptamers, and for the study of the ribosomal translation system. One of the most common procedures involves chemical acylation of the 3’-end dinucleotide of a tRNA of choice with the UAA of choice. The tRNA is then prepared without the 3’-end dinucleotide and then the acyl-dinucleotide can be ligated on using T4 RNA ligase to afford the full length misacylated tRNA (Figure 2.I.A). This approach was used in many early studies on mRNA display. For instance, Roberts employed a chemoenzymatic approach to incorporate biocytin into mRNA display libraries for streptavidin capture assays.115,116 More recently, the Ito group has used chemoenzymatic acylation of tRNAs for the development of peptide aptamers and probes containing UAAs in ribosome display selections. They have incorporated UAAs such as a photo-responsive ε-(azobenzoyl)-lysine,117 a fluorogenic 7-nitro-2,1,3-benzoxadiazole conjugated aminophenylalanine,118,119 the small molecule purvalanol conjugated aminophenylalanine,120 and an electroreactive 3,4-ethylenedioxythiophene conjugated aminophenylalanine.121
Figure 2.
Substrate scope of genetically encoded peptide diversification by (I) chemical aminoacylation, chemical N-methylation, and native aaRSs, and (II) orthogonal aaRSs. (I-A) Chemical scheme for the chemical acylation of tRNAs by T4-RNA ligase, and the chemical transformation of acylated amino acids to N-methylated amino acids acylated on tRNAs. (I-B, C, D, E) Examples of substrates that have been incorporated using the indicated native aaRSs, the structures are not all inclusive. Green refers to the total number of UAAs that were aminoacylated by native aaRSs. Purple refers to the number of UAAs efficiently translated into model peptides with a translation efficiency greater than 25%. (II-A, B) Structures shown are the unnatural amino acids that have been incorporated using MjTyrRS and MmPylRS mutants in a GEL setting. Red indicates the number of substrates for various mutants of the orthogonal aaRSs, but that may not have been used in a GEL. aServes as initiator, although inefficiently, bLoaded by IleRS and ValRS, however only efficiently translated when loaded by IleRS, cEfficient in elongation but not initiation
Alternatively, preacylated tRNAs have been chemically modified to introduce new functionality. The pool of natural amino acids can be permethylated by a reductive amination protocol involving an intermediate o-nitrobenzylamine protection step to prevent deleterious demethylation (Figure 2.I.A).122 Charged tRNAs prepared in this way have proven competent substrates for the ribosome and libraries of N-methyl peptides can be prepared and selected. Notably, although N-methyl versions of all proteinogenic amino acids prepared in this manner are accepted by the ribosome, N-methylated leucine, threonine, and valine are most efficiently incorporated into translated peptides.123 Similarly, preacylated proteinogenic tRNAs can be converted to their α-hydroxy acids by deamination with nitrous acid124 and incorporated into polyesters via the ribosome, although this chemistry has not been exploited with GELs.
Native tRNA Synthetase/tRNA Pairs
Despite the high specificity and tight editing mechanisms of most natural tRNA synthetases, they have proven unexpectedly promiscuous towards UAAs. This promiscuity no doubt is a result of the natural amino acids not having to compete with UAAs under normal physiological conditions. The relatively recent development of translation systems composed almost entirely of purified components125,126 has allowed elucidation of the rather broad substrate promiscuity of E. coli aaRSs in particular and this promiscuity has then been exploited in a number of in vitro GELs for genetic code reprogramming. Natural amino acids need only be omitted from the translation mix and appropriate UAAs added in their stead. Cross-compatibility between different UAAs should be taken into account when devising UAA cocktails for this approach. An extensive study of native aaRS/UAA compatibility was carried out by Szostak and Hartman by means of a high-throughput MALDI-TOF assay.72,73 This work demonstrated that nearly 100 UAAs could be efficiently ligated to tRNAs by a native E. coli aaRS and that many of these could also be efficiently translated into test peptides, allowing the synthesis of peptides containing numerous, consecutive UAAs (Figure 2.I.B–E).76 Notably, although some of the promiscuity may have seemed predictable based on structural similarity to the cognate amino acid, there were several cases of aaRSs taking analogs of a non-cognate amino acid. Perhaps most strikingly, the MetRS was seen to readily accept the side chain methyl esters of Asp and Glu.72 MetRS was also able to accept the only translated α-hydroxy acid, α-hydroxy methionine, while ValRS was able to accept two α, α-disubstituted amino acids, 1-aminocyclopentanoic acid and 1-aminocyclohexanoic acid (Figure 2.I.B).76 This unexpected promiscuity underscores the utility of this kind of study in uncovering the innate flexibility of native aaRSs. In sum, these studies found 17 out of 20 aaRSs72 that could take at least one analog and up to 13 different amino acid codons could be simultaneously reprogrammed.76 Several groups have since gone on to use the insight from these broad promiscuity assays for mRNA display campaigns with expanded chemical diversity. For example, L-canavanine, L-threo-β-hydroxy aspartic acid, and ten other UAAs were used in one such campaign,98 while homopropargylglycine was used to replace methionine to allow “click glycosylation” for preparation of libraries of glycopeptide analogs.105 In a promising variation on this method, Roberts and colleagues expanded the capabilities of native aaRSs further still by introducing an editing deficient mutant of the ValRS. This mutant allowed the incorporation of various UAAs, including α, α-disubstituted amino acids and constrained β-amino acids, into their libraries (Figure 2.I.B, C).127,128 Thus, much diversity can be accessed by in vitro translation systems without resorting to exogenous acylation strategies.
Flexizyme Technology
To date, the set of evolved ribozymes known as Flexizymes (or Fx for short) have proven the most robust and versatile tool for non-cognate loading of tRNAs and genetic reprogramming in in vitro translation systems. Fxs have been essential in elucidating the exceptionally broad promiscuity of the ribosome. They nucleate the association between a suitably protected carboxylic acid and a tRNA of choice to effect acylation of the tRNA 3’-OH in a manner similar to class II aaRSs.129,130 Because Fxs recognize a small epitope, three bases on the 3’ end of the acceptor stem of the tRNA, they are particularly versatile and can be employed with a broad array of tRNAs. Substrate recognition typically requires the presence of an aromatic group on the substrate molecule and is thought to involve pi-pi interactions. Three different Fxs have been developed to date, each recognizing a different side chain or carboxylate ester to allow for a broad variety of UAAs to be incorporated into GELs (Figure 3). The broadly promiscuous dinitro-Fx (dFx) recognizes the dinitrobenzyl esters (DBE) (Figure 3A.1) of amino acids lacking an aromatic side chain. For those amino acids that contain an aromatic side chain, enhanced Fx (eFx) accepts the cyanomethyl ester (CME) group as well as the somewhat more activated 4-chlorobenzyl thioester (CBT) (Figure 3A.2).74 Finally, amino Fx (aFx) has been developed to recognize solubilizing aminobenzyl thioesters (ABT) (Figure 3A.2) for use with amino acids with poor aqueous solubility.131 This array of Fxs has facilitated the incorporation of hundreds of different amino acids into peptides and GELs. While not all amino acids discussed below have been used in GEL selections, there is little barrier to their use in such libraries based on the robust in vitro translation assays that they have already surmounted.
Figure 3.
Substrate scope of genetically encoded peptide diversification by Flexizymes. (A) Ester functional groups appended onto the C-terminus of amino acids for recognition by the various Fxs. (B-H) Substrates that have been shown to be accepted by one of the three different Fxs and shown to be efficiently incorporated into a model peptide (>10% translation efficiency). Not all amino acids shown have been used in GELs. Red indicates the number and details of amino acids that have been incorporated by reprogramming the initiator codon and tRNA. Blue indicates the number and details of amino acids that have been incorporated via elongation codons and tRNAs.
Fx is particularly well suited to reprogramming translation initiation. Since the α-amine of the initiator amino acid is not required for peptide bond formation, there is seemingly less penalty for exotic groups at this position and significant opportunity for structural and functional diversity. Accordingly, the initiator tRNA can be used as a testing ground for the steric and functional limitations of a wide array of carboxylic and unnatural amino acids that can be loaded via Fxs. The long list of acids incorporated into the initiator position of GELs via Fxs includes: both L- and D- stereoisomers of all 20 natural amino acids,132,133 amino acids with large, bulky substituents such as L-carboranylalanine,134 N-alkyl-amino acids such as D- and L- N-Me amino acids and β-proline,34 thiol-reactive carboxylic acids such as m-chloromethylbenzoic acid,34 peptides containing UAAs, β-, and γ-amino acids,135,136 among others (Figure 3B–D, F, G).137–139 Notably, preacylation of the α-amino group of initiating amino acids, as in dipeptides,136 often improves the translation efficiency.
One of the most useful functional groups on initiating amino acids incorporated with Fxs is the N-terminal chloroacetyl group. This functional group is used frequently to set up a cyclization reaction with downstream Cys residues via a spontaneous SN2-type reaction that can occur during translation. Libraries of cyclized peptides have been generated using ClAcL/DF,21,84,140–142 ClAcL/DW,43,132,143–146 ClAcL/DY,45,132,147 ClAc-L-carboranylalanine,134 and p-(N-chloroacetylacetoamido)benzoyl-L/DF,21 among others (Figure 3B.2). Notably, libraries of randomized peptides can frequently display more than one cysteine for cyclization. In this case, the N-terminal chloroacetyl groups typically undergo cyclization with the nearest Cys, unless it is directly adjacent to the chloroacetyl group, in which case the next Cys downstream will serve as the nucleophile.148 Because of the robustness and reliability of this chemistry, the chloroalkane cyclization has been used in several other contexts, including side chain-to-side chain macrocycles and bicyclic and tricyclic macrocycles to increase structural diversity.135,149–151 One other cyclization technique that is accessible via initiator reprogramming is intramolecular oxazole formation between a 5-hydroxytryptophan and an N-terminal benzylamine-phenylalanine under oxidizing conditions (Figure 3B.2).152 Given the versatility of the initiator position, other N-terminal modifications can still be imagined.
Fx has also proven competent for introducing a variety of other UAAs at the level of translation elongation. As with initiation, elongation can accept D-amino acids although some modifications to standard translation protocols are required to incorporate multiple consecutive D-amino acids (Figure 3C.2). Under standard conditions, 12 of the 19 D-stereoisomers of natural amino acids can be incorporated into multiple peptide sequences at least once at or above 10% translation efficiency.153 Consecutive incorporations of D-amino acids can be achieved through the addition of EF-P, an elongation factor, which is normally employed by eubacteria to facilitate translation of poly-proline tracts.154 Additional changes to the T-stem and D-arm of tRNAs are necessary to facilitate EF-P interactions. As an example of the limits of this approach, D-serine can be incorporated simultaneously at up to ten consecutive residues.155
Fx can charge tRNAs with N-methyl amino acids as well. Although all N-methyl analogs of proteinogenic amino acids can be loaded by Fx, only aromatic, non-charged, non-branched, and sterically small amino acids, such as Tyr, Phe, His, Leu, Ser, Gly, and Ala achieve greater than 10% translation efficiency. This subset is well tolerated and up to 10 can be incorporated sequentially into model peptides to give short, hyper-methylated peptides (Figure 3F.1).84 In a dramatic extension of this proficiency, Fx has been exploited to incorporate N-alkyl glycine peptoids into mRNA display libraries. Branched alkyl, non-branched alkyl, and functionalized N-alkyl,85 as well as cyclic N-alkylated residues could all be incorporated efficiently (Figure 3F.2 and 3F.3). Of 21 cyclic N-alkyl residues tested, all could be incorporated a single time, and 15 could be incorporated consecutively, up to four residues in a row. As in the case of D-amino acid incorporation, EF-P could be added to enhance sequential incorporation of the N-alkyl residues.142 Charged groups, such as amines and carboxylic acids prove challenging substituents for these peptoids, as has also been seen with the more traditional N-methyl amino acids. Side chain protecting groups can be employed to circumvent the poor tolerance of charged functional groups. Fx incorporation of azides and methyl or benzyl esters allow the unmasking of the respective amines and carboxylates (Figure 3F.4),75 thus effectively completing the set of amino acid peptoid analogs that can be accessed by Fx.
Remarkably, translation elongation also allows changes to the spacing between the carboxylate electrophile and amino nucleophile and even direct replacement of the native amine with alternative heteroatom nucleophiles. Suga has shown incorporation of both β- and γ-amino acids via Fx-mediated tRNA loading. 13 of 16 β-amino acids tested could be incorporated a single time with efficient translation, including amino acids with L- and D- stereochemistry, and even one charged amino acid, although with low translation efficiency compared to other amino acids.156 Recently, Suga and colleagues showed the incorporation of the different stereoisomers of the cyclic β-amino acids, 2-aminocyclohexane-carboxylic acid and 2-aminocyclopentane-carboxylic acid.157 EF-P, again, enhanced consecutive incorporations (Figure 3H.1).157,158 γ-Amino acids are most efficiently incorporated at the N-termini of dipeptides during translation initiation.136 However, select cyclic γ-amino acids can be incorporated during elongation by using the EF-P helper strategy (Figure 3H.2).141 Additionally, α-hydroxy acids and α-thioacids have been incorporated during elongation (Figure 3E.1 and 3E.2). Sequential incorporation of multiple α-hydroxy acids has allowed the translation of polyesters,159 while the site selective incorporation of thioacids enabled novel native chemical ligation strategies135 discussed in detail below.
Orthogonal and Engineered aaRS/tRNA Pairs
The use of orthogonal aaRS/tRNA pairs has become perhaps the most common way to incorporate UAAs into proteins in vivo. Liu and Schultz have defined an orthogonal aaRS/tRNA pair as an aaRS that is specific for only its cognate amino acid and no other natural amino acids, and that will only recognize its tRNA partner.49 In most cases, these orthogonal pairs have been adapted from widely different organisms in order to predispose orthogonality, however mutagenesis and selection is often still necessary to ensure orthogonality to the host organism. The thermophilic methanogenic archaea, Methanococcus jannashii and Methanococcus mazei have provided two of the most commonly exploited orthogonal aaRS/tRNA pairs in the M. jannaschii TyrRS (MjTyrRS) and M. mazei PylRS (MmzPylRS),49 although more orthogonal pairs are being discovered as informatics and technology improve.160 Both can be made to accept an amber anticodon on their respective tRNAs161,162 and thus can incorporate UAAs at a dispensable codon for genetic code expansion. The MjTyrRS is a class I aaRS that has been used to incorporate more than 38 different primarily aromatic UAAs at multiple different codons into proteins (Figure 2.II.A).49 The plasticity of the substrate binding pocket and active site allows for mutations that expand the space available for binding large aromatic substrates.49,163,164 The MmzPylRS is a class IIc aaRS, which exhibits broad substrate specificity that can readily be expanded by mutations to its C-terminal catalytic domain (Figure 2.II.B). For example, the PylRS Y384W mutant has an expanded catalytic domain that allows for the incorporation of multiple lysine derivatives.165 Other PylRS mutants, that accommodate various sizes of non-canonical amino acids have been identified, and more than 100 non-natural amino acids and their analogs have been incorporated into proteins in vivo and in vitro.162 UAA substrates tend to be aromatic or lysine derivatives for MjTyrRS mutants and MmzPylRS mutants, respectively, as they best mimic the natural substrates of the two aaRSs. However, substrates as complex as tetrazine-phenylalanines, hydroxyquinolines, and coumarin UAAs via MjTyrRS mutants,163 and a cyclooctyne-lysine derivative, phenylalanine derivatives, and a-hydroxy acids via PylRS mutants162 have been successfully incorporated into proteins in vivo. Both orthogonal aaRS/tRNA pairs have since been transitioned to use in GELs to add in UAAs at the amber codon position. This allows for genetic code expansion of a broad array of aromatics and lysine derivatives in GELs and is readily available for in vivo GELs because the tRNA and aaRS can be expressed in the organism of the display technology.
Orthogonal aaRS/tRNA pairs have led to diversified in vivo display strategies. SICLOPPS and plasmid-encoded libraries have both been modified to use MjTyrRS mutants for incorporation of various aromatic residues. In a first application, Schultz and coworkers incorporated p-benzoylphenylalanine (pBzF) (Figure 2.II.A) into a SICLOPPS library using a mutant MjTyrRS specific for pBzF.15,166 Notably, in the subsequent selection against HIV protease, pBzF served as a covalent modifier of an active site lysine.15 Orthogonal aaRSs have also allowed the direct in vivo cyclization of plasmid-encoded libraries without need for split inteins, which are required for cyclization in SICLOPPS libraries. In the earliest work of this kind, Fasan and colleagues introduced novel nucleophilic UAAs N-terminal to a C-terminal intein to allow cyclization onto the intein-derived intermediate thioester. Early nucleophiles were amine side chains, such as p-amino phenylalanine (pAmF) or O-2-aminoethyl-tyrosine (O2ameY),167,168 (Figure 2.II.A) but later iterations employed pendant thiols, such those present in 3-amino-4-mercaptomethyl-phenylalanine (AmmF) and 3-(2-mercapto-ethyl)-aminophenylalanine (MeaF) to accelerate the cyclization in an NCL-like fashion.82,167 This approach obviates the need for the N-terminal intein fragment and allowed novel diversity elements that impact macrocycle conformation, such as the aryl rings of the pAmF and tyrosine derivatives. Still more recent iterations of this approach have incorporated electrophilic UAAs, such as O-(2-bromoethyl)-tyrosine (O2beY),81,169 (Figure 2.II.A) at the N-terminus of plasmid-encoded libraries that can cyclize with downstream cysteine residues. Several mutant MjTyrRSs have been the workhorses of this approach.
Phage display has also been enhanced by the use of MjTyrRS and PylRS mutants to incorporate UAAs. The Schultz group first published the use of MjTyrRS mutants specific to UAAs in phage display in 2004 to incorporate O-me-tyrosine,170 p-azidophenylalanine,171 p-acetylphenylalanine,172 pBzF,166 and 3-(2-naphthyl)alanine173 (Figure 2.II.A) in a library of peptides.78 The group expanded on this technology when they used UAA-specific MjTyrRS mutants to incorporate sulfotyrosine,174 p-acetylphenylalanine, bipyridal-alanine,175 and p-boronophenylalanine176 (Figure 2.II.A) in a phage display library of antibody fragments.177 Use of multivalent hyperphage phagemid display rather than wild-type M13 phage was essential to these efforts. The hyperphage present a wild-type pIII phenotype, but lack a functional pIII gene while still successfully infecting E coli, ensuring that the sole source of pIII is the pIII-library member fusion in the phagemid.178 These hyperphage enabled targeted selections, alongside the orthogonal, engineered MjTyrRS mutants specific to p-boronophenylalanine and bipyridal-phenylalanine to incorporate the UAAs into phage display libraries.79,179 More recently, Fasan and colleagues used the O2beY specific MjTyrRS mutant169 with a similar phagemid strategy to incorporate O2beY into a phage display library for cyclization with a downstream cysteine residue.80 Moving away from large aromatic groups, Nε-butyryl-lysine (Figure 2.II.B) was incorporated via the PylRS Y384W mutant165 to mimic natural PTMs that are read by epigenetic regulators in the cell.83 The same group also utilized the same PylRS mutant to translate Nε-acryloyl-lysine (Figure 2.II.B) into a phage display library for spontaneous cyclization with a downstream cysteine residue.81
Advances in Genetic Code Expansion
Most of the technologies mentioned above allow significantly expanded translational diversity through codon reprogramming, but even greater diversity can be achieved by splitting redundant codons or creating new, expanded codon sets, i.e. genetic code expansion. Fx has been used to effectively split codon boxes and increase the number of amino acids available for each position of a randomized mRNA display library. By using a stripped down in vitro translation system with only artificial tRNAs supplied in trans, Suga and colleagues reduced the codon alphabet to 32 minimally tRNASNN transcripts (S = G or C) that removed wobble-based redundancy. 29 of these tRNAs could be used to encode the 20 proteinogenic amino acids plus a stop codon, while the remaining three could be utilized for UAA incorporation.143 In this way, libraries containing 23 unique amino acids at variable positions could be made and used in selections.147 Alternatively, Sisido and colleagues have expanded the genetic code by employing four base codons.180,181 In this case, two Arg codons, and a Gly codon were selected for reprogramming based on their rare usage in the E. coli genome and therefore low gene copy and transcription levels. Artificial four-base pair anticodon tRNAs could be chemoenzymatically acylated with UAAs and it was found that these competed effectively with triplet decoding by the native tRNAs in a cell-free translation system. While there is some correlation between translation efficiency and the fourth base, in most cases all four bases can be used in the fourth position,182 in essence allowing one three-base codon to be replaced by four four-base codons. This approach allowed mRNA display selections with libraries exhibiting an additional three UAAs on top of the natural amino acids.183 More recently, this approach has been extended to the incorporation of UAAs into phage using an evolved PylRS. Chin and coworkers showed that the UAA p-propargyloxy-L-phenylalanine could be incorporated at a four-base codon.184 Notably, to the best of our knowledge, this report is also the first example of the use of an orthogonal ribosome in a GEL. This could greatly enhance the ability to utilize four base codons in future GEL designs.
Limits of Translational Incorporation of Diversity Elements
Cumulatively, between chemoenzymatic strategies, both native and orthogonal aaRSs, and Fxs, there are now a number of tools for pushing non-natural building blocks through the ribosomal translation machinery and into genetically encoded libraries. Each of these diverse strategies presents its own advantages and limitations that recommend it for specific GELs. Perhaps the most salient distinction between these loading methods is between orthogonal aaRSs, which can be used with in vivo, cell-based GELs such as SICLOPPs and phage display, and chemoenzymatic and Fx-based methods, which, thus far, are only compatible with in vitro GELs, such as mRNA display. Orthogonal aaRSs by definition exhibit the selectivity necessary to discern between the native, proteinogenic amino acids and UAAs but also, presumably, benefit from increased cellular stability relative to RNA-based Fxs. aaRSs have benefits for in vitro display libraries as well: they accept readily accessible, unprotected amino acids, act catalytically to reacylate tRNAs as they are released from the ribosome and they can be employed in situ, at lower concentrations than Fx and without arduous prior purification of the acyl-tRNAs. That said, the substrate scope of aaRSs with respect to both amino acids and tRNA partners is severely limited and finding or engineering new variants is still non-trivial. From the standpoint of versatility, Fxs are powerful tools: Fxs now exist for a wide array of amino acids and they can easily be adapted to essentially any tRNA, since they recognize a minimal 3-base pair epitope. Still, the need for super-stoichiometric quantities of acyl tRNAs means that Fxs will inevitably be limited in terms of library diversity, since the translation mixtures will only be able to accommodate so much RNA in solution.48,74 A hybrid strategy, that marries the flexibility of Fxs and the efficiency of aaRSs, along with advances in genetic code expansion strategies, would doubtless allow a diversity of GELs not yet seen in the literature.
Post-Translational Modifications.
This section reviews site-specific PTMs that have been made on genetically encoded molecules and libraries. Both chemical (cPTMs) and enzymatic (ePTMs) transformations have been harnessed to diversify GELs post translationally. To date, non-enzymatic chemistries have been used for most of the diversity elements post-translationally installed on GELs, although enzymes have gained traction in recent years. Additionally, while there is a large and growing arsenal of biocompatible chemical transformations185–189, only a modest number have been adapted for modifying GELs. Chemistries that have been used to modify GELs are necessarily robust and orthogonal to the genetic material and exploit a limited number of reactive handles present in canonical or else unnatural amino acids and building blocks. Cysteine thiols are easily the most utilized natural reactive handles for cPTM of GELs and have been employed in numerous applications (Figure 4). Similarly, N-terminal amines also present discernable reactivity and have been selectively modified or converted into handles for further PTM on display libraries (Figure 5A). Other canonical amino acid functional groups, such as lysine side chain amines, the carboxylic acids of aspartic or glutamic acid residues, or the phenol groups of Tyr residues, have also been used as sites for cPTM on display molecules, but provide significantly less selectivity.190–196 While these PTMs may be beneficial for imaging and drug delivery efforts, they are likely unconducive towards affinity selections, as over modification may confound selection results and/or compromise the integrity, infectivity, or growth of library members; thus, these nonspecific modifications are not reviewed here. Indeed, because site selectivity is such an important consideration in the PTM of GELs, non-natural, bioorthogonal functional groups, such as azides and alkynes, are also popular handles for post-translational diversification and have been used in a number of applications (Figure 5B).
Figure 4.
GEL diversification through reactions with cysteine, including (1) alkylation, (2) cyclization, (3) peptide extension, (4) DHA installation, and (5) DHA conjugate addition. Light grey boxes depict representative reagents that have been used to chemically diversify cysteines on GELs for a given type of reaction. Colored dots indicate the display systems where these GEL modifications have been made, where purple = phage display, green = cell-surface display, and yellow = mRNA display.
Figure 5.
GEL diversification through reactions with (A) N-terminal amines, (B) click reactions, and (C) enzymatic transformations. (A) Reaction of N-terminal amines with: 1. sodium periodate to form aldehydes and subsequent diversification with chemical reagents outlined in light grey boxes, 2. chemical linkers to form macrocycles, or 3. an N-terminal remainder of a split intein (IntN) to enable synthetic peptide ligation. (B) Copper mediated click reactions between translated azides/alkynes of GELs with their complementary chemical reagent to enable either: 1. side chain modifications or 2. cyclizations. (C) Promiscuous enzymatic reactions that diversify GELs through: 1. Thioether formation, 2. Peptide ligation and 3. indolizidinone formation. Colored dots indicate the display systems where these GEL modifications have been made, where purple = phage display, green = cell-surface display, and yellow = mRNA display.
Chemical Modifications (cPTMs)
Side Chain Modifications
Cysteine alkylation or arylation with alkyl or aryl halides has been used extensively with various GELs, including phage, mRNA display, and cell-surface display libraries. This basic SN2 chemistry has been used to fit libraries with various pharmacophores,57,104 fluorophores,103,197 and carbohydrate-based epitopes (Figure 4.1).87 In a recent, novel application, a phage library was fitted with a boronic acid functionality in order to covalently target bacterial cell walls.90 Importantly, when applied to phage, this chemistry has been employed in conjunction with a mutant M13 phage that lacks cysteines in the pIII coat protein.198 This disulfide-free pIII variant can improve regioselectivity in the cPTM of cysteine containing phage display libraries. However, it also reduces phage infectivity, thus requiring large culture volumes to generate sufficient infective phage to encompass library diversity.61 In addition to alkylation, cysteine residues in phage libraries have been coupled with synthetic peptides via conjugate addition to maleimide linkers (Figure 4.3).86 Cysteines on mRNA displayed peptides have also been post-translationally eliminated via α,α’-dibromoadipic-bis-amide to furnish dehydroalanines (DHAs) (Figure 4.4), which can subsequently be reacted with carbohydrate thiols to form glyclosylated macrocycles (Figure 4.5).95 Overall, canonical side chain cPTM of GELs has almost exclusively been limited to cysteine thiols, as other potentially reactive amino acids bearing amines or activated aryl positions are less likely to provide favorable site selectivity.
Some UAAs have also undergone PTM to expand GEL diversity, with the most common example being a copper-mediated click reaction between a translated azide or alkyne UAA and the complementary reactive handle on the PTM. Notably, there have been some reports of reduced phage infectivity199 or oxidative damage to DNA200 during Cu-Activated Azido Alkyne Cycloaddition (CuAAC); this reduction in genetic viability however may be attenuated with radical scavengers like DMSO200 or reducing agents like sodium ascorbate,201,202 and several publications report successful PTM of GELs using CuAAC.52,92,105 For example, Krauss and coworkers reprogrammed Met with homopropargylglycine and, by capitalizing on the natural promiscuity of the native Met-RS, translated a Met-deficient mRNA display library with reactive alkyne handles. They then performed CuAAC to append branched mannose-azide moieties to the library, creating a library of glycopeptides (Figure 5B.1).105 Strain-promoted click chemistry has also been performed on azide-containing pVIII proteins of M13 phage, suggesting feasibility of click reactions on phage libraries.203 Click chemistry has also been used to expand structural diversity of GELs with mono-, bi-, and α-helical cyclizations, all of which will be discussed in further detail. Additionally, selenium containing UAAs have also undergone PTM, specifically oxidation, to afford DHAs. Selenalysine for instance has been incorporated into an mRNA display library using native Lys-RS translation machinery, treated with hydrogen peroxide to furnish a DHA, and spontaneously reacted with downstream cysteines to generate a lanthipeptide library for functional selections (Figure 4.5).204 Other UAA scaffolds have also been accessed through chemical modification; for example, the post-translational deprotection of several Fx-mediated N-alkyl UAAs to reveal their electrically charged derivatives has been performed on model mRNA display genes.75
N-Terminal Modifications
The N-termini of display libraries are often chemically distinguishable because they can present uniquely reactive free amines that are significantly less sterically hindered than other library portions, making them readily accessible for cPTM. In GELs that are generated in vivo in bacteria, N-terminal amines are innately available for modification, because the formyl group of the initiator formyl methionine is typically removed by deformylases or aminopeptidases immediately after translation. However, GELs produced by in vitro bacterial translational machinery, such as those in mRNA display, retain this formyl group, so deliberate addition of a deformylase or aminopeptidase is needed to reveal this N-terminal residue for these methods. Use of eukaryotic lysate for library translation is an alternative approach to immediately generate N-terminal amines poised for cPTM. Regardless, N-terminal amines are frequent targets for cPTM.
Chemical modification of N-terminal serines and threonines has been particularly useful for diversifying phage libraries. These residues can be converted to highly reactive and biorthogonal aldehydes by oxidation with sodium periodate. This group can in turn be reacted with a number of different functional handles (Figure 5A.1). In one example, thus formed aldehydes were reacted with alkoxylamines to yield the corresponding oximes.53 A variety of alkoyloxylamine substituents could be tethered to the libraries by this chemistry, including biotin,53,110 sulfonamides,101 and carbohydrates.53,101,205–207 As seen with other oxime ligations, the reaction rate of this chemistry on phage can be significantly enhanced by addition of aniline as a nucleophilic catalyst. Synergizing oxime ligation with a nucleophilic aniline group in a 2-amino benzamidoxime derivative of biotin allowed intramolecular ring formation on a phage library via a modified Pictet-Spengler reaction.58 In an alternative approach, serine or threonine-derived N-terminal aldehydes have also been reacted with phosphonium ylides in a Wittig reaction to form internal olefins, which have subsequently been derivatized by conjugate addition with thiol nucleophiles or Diels-Alder reaction with cyclopentadiene.59
N-terminal cysteines have also been exploited for site selective reactivity in display libraries. In early work, N-terminal native chemical ligation (NCL) of a UAA-containing synthetic peptide with a small phage library bearing an N-terminal cysteine was used to install proteins on phage.107 More recently, timed deprotection of mRNA displayed peptides bearing an N-terminal thiazolidine has allowed for an intramolecular NCL to form backbone cyclic macrocycles.135 In further thiazolidine chemistry, a phage library with an N-terminal cysteine, selectively revealed through a Factor Xa cleavage site, has been reacted with a 2-formylphenylboronic acid biotin moiety to afford N-terminal thiazolidino boronates.208
Finally, split inteins have been expressed on display surfaces to enable trans splicing with synthetic peptide or protein fragments (Figure 5A.3). Using a monovalent phagemid system, Mootz and coworkers split the Ssp DnaB intein between the pIII coat protein of M13 phage and a maltose-binding protein or a biotinylated synthetic peptide for trans splicing.209 This auto-catalytic ligation required initial expression of a solubility tag and a relatively large intein sequence on pIII, but successful reaction with the complementary synthetic intein results in removal of these unwanted domains, making it more feasible as a library diversification strategy. Additionally, the M86 intein has been used to ligate a small molecule fluorophore and hydroxylamine-bearing synthetic peptide fragments onto cell-surface displayed peptides.96 The relatively small 11 residue N-terminal portion of the M86 intein is readily accessible by solid-phase peptide synthesis, but also requires the use of solubility tags for successful splicing.
Macrocyclization Chemistries
Chemical macrocyclization has been used heavily with GELs. This approach generally involves reacting a bivalent chemical linker with a library comprised of members with two or more reactive handles to conformationally constrict or staple the library members. Notably, many of the same chemistries have been used repeatedly to afford different types of scaffolds simply by altering the genetic composition of the library or by synergizing orthogonal cyclization strategies. By far the most common macrocyclization chemistry for GELs is cysteine alkylation. Libraries with fixed cysteines flanking the randomized portions can be reacted with bifunctional alkyl halide linkers to form side chain to side chain macrocycles (Figure 4.2). A wide array of linkers have been used for this kind of chemistry,60,91,98,128,210 including some more exotic examples such as dichloroacetone, which can be reacted with hydroxylamines in situ to yield the corresponding oximes,88 or 1,5-dichloropentane-2,4-dione, which can be reacted with hydrazines to further increase diversity of the resulting modified libraries via Knorr pyrazole synthesis.211 An additional cyclization involves the reaction of the N-terminal free amine and side chain amine of a fixed C-terminal lysine with the cross-linking agent disuccinimidyl glutarate (DSG) to form head to side chain cycles (Figure 5A.2).23,46,93,212 DSG has been used primarily with mRNA display libraries,23,46 where library translation with rabbit reticulocyte lysate provides immediate access to the free N-terminal amine which would otherwise be formylated in prokaryotic translation systems, but modification of yeast display libraries with DSG has been recently reported.212 An alternative N-terminal amine cyclization strategy involves reacting a divalent linker, sporting both a 2-((alkylthio)(aryl)methylene)malononitrile (TAMM) group and alkyl chloride, with a library containing fixed N- and C-terminal cysteines to afford 2-aryl-4,5-dihydrothiazole (ADT) containing macrocycles (Figure 5A.2).213 Several other cyclization approaches have exploited the reactivity of translated UAAs: the UAA p-acetylphenylalanine for example has been translated with an orthogonal synthetase on phage display particles and reacted with an N-terminal hydroxylamine to cause cyclization through oxime bond formation96 and click chemistry has been used to connect azide and alkyne-containing UAAs.52
Cyclizations can also induce library α-helicity by bringing specific peptide fragments in close proximity and encouraging α-helix formation. A partially randomized phage display library sporting two fixed cysteines four residues apart was modified using the same cysteine thiol/alkyl halide linker strategy described above to impose an α-helical conformation.214 Employing the use of copper-mediated click chemistry, a bacterial cell-surface display library containing two fixed azide UAAs was conformationally stabilized with a propargyl ether linker (Figure 5B.2).92 Other types of scaffold stabilization have been applied as well; GEL cyclization with an aza-benzene photo-responsive linker has enabled cyclic peptides that can switch between cis- and trans- isomers upon exposure to light, rendering peptides active or inactive depending on their conformation (Figure 4.2).60,91,215
Many of the same chemistries have also been adapted to allow bicyclization and tricyclization of display libraries, providing access to highly rigidified and unusual three-dimensional structures that prove potent ligands. For example, the cysteine thiol alkylation chemistry has been used to form bicyclic phage libraries, wherein linear libraries containing three fixed cysteine residues are reacted with trivalent aryl or alkyl halides, such as tris-(bromomethyl)benzene (TBMB) (Figure 4.2).14,50 Bicyclization of phage libraries with a tetravalent adamantane-based linker has also been reported, with subsequent linker functionalization made possible via the remaining unreacted alkyl halide.97 Vast scaffold diversity can be achieved by designing libraries to allow for multiple, randomized macrocyclization patterns. For instance, an NNK10 tetravalent cysteine library, with three fixed cysteine residues and one randomized, was displayed on phage.51 By reacting two equivalents of a thiol-reactive linker with this new library, simple SN2 chemistry generated bicyclic libraries with 30 possible macrocyclic scaffolds per linker. Reacting the library with six distinct chemical linkers afforded up to 180 structurally unique bicycles for a library with ten randomized residues. This semi-randomized cysteine bicyclization strategy has also been performed with two fixed position and two randomized position cysteines.216 Both provide unique examples of exploiting a tried and true cyclization method to access a wealth of scaffold diversity. Notably, a similar tetravalent cysteine library has also been post-translationally oxidized to create structurally diverse bicycles linked through simple disulfide bonds.106
Combining two cyclization strategies that are orthogonal to each other has been used as an alternative way to form bicyclic peptide libraries. In this vein, Hartman and coworkers reported the use of sequential thiol alkylation and click reactions on an mRNA display library.52 In this study, Met and Phe were reprogrammed with L-β-azidohomoalanine and p-ethynyl-L-phenylalanine, respectively, and translated using cognate Met-RS and Phe-RS A294G into libraries containing two fixed cysteine residues. The libraries first underwent monocyclization with α,α’-dibromo-m-xylene, then copper-mediated azide-alkyne bicyclization to afford overlapping, θ-bridged peptide scaffolds.
Enzymatic Modifications
Although there are relatively few reports of enzymatic diversification of GELs, enzymes are attractive tools for mild, biocompatible chemistry that are gaining traction. In early work, the kinases Blk, Lyn, c-Src, and Syk were used to phosphorylate tyrosine residues in a phage display library in order to enrich for and identify peptide sequences similar to the recognition motifs for these kinases.99,100 Since then, several other reports have also used GELs to enrich for substrate sequences for kinases, proteases, and other enzymes.89,217–223 Alternatively, in an approach to create more metabolically stable peptides, several libraries have been “pre-selected” against proteases before target panning to enrich for protease resistant and thus serum stable peptides.46,216 Additionally, Sortase A from Staphylococcus aureas has been used to diversify phage particles with synthetic peptides (Figure 5C.2); phosphorylated224 and biotinylated225 peptides, as well as pre-folded GFP,225 all containing LPXTG recognition motifs, were site-specifically ligated onto N-terminal glycines in the M13 phage pIII coat protein. In the same work, another Sortase variant from Streptococcus pyogenes, was also used to modify N-terminal alanines of high copy pVIII coat proteins with a fluorophore and single domain antibody.225 Although these examples have limited potential to incorporate new diversity elements into GELs, they provided key validation of enzyme compatibility with GELs and important tools for subsequent efforts.
Promiscuous enzymes from natural product biosynthesis may prove a rich source of new PTMs for diversifying GELs. Enzymes from ribosomally synthesized and post-translationally modified peptide (RiPP) biosynthetic pathways have proven particularly useful in this regard. In recent work, the RiPP lanthipeptide biosynthetic machinery has been used to form relatively large, randomized libraries with cell-surface94,226 and phage display36,94 technologies, as well as plasmid-encoded libraries (Figure 5C.1).18 The cell surface display of a thioether stabilized peptide library was initially achieved by Moll and coworkers on the bacterial cell wall of L. lactis, which supports the dehydratase (NisB), cyclase (NisC), and transporter (NisT) enzymes for the formation of class I lanthipeptide nisin. By translating their library with a cell-wall anchoring motif containing a Sortase recognition sequence, the authors could translocate and retain their library within the cell membrane, then covalently attach it to the peptidoglycan with Sortase to enable cell-surface display.226 More recently, the van der Donk lab achieved display of lanthipeptide libraries on both yeast and phage surfaces. They fused their yeast display library to the C-terminus of the yeast surface protein agglutinin. To overcome library translocation issues, they targeted a bifunctional lanthipeptide dehydratase and cyclase, LctM, to the endoplasmic reticulum so that thioether PTM could be performed after the peptide library crossed the cell membrane. In phage, the authors constructed a phagemid that fused the C-terminus of their library and a Tat cell-penetrating peptide to the N-terminus of a truncated pIII coat protein of M13 phage. The Tat peptide was introduced to facilitate library export into the periplasm of E. coli after PTM. This phagemid was co-expressed with a modification plasmid containing NisB and NisC, as well as a helper phage that supplied remaining required phage proteins. Post-display addition of the leader peptidase NisP then yielded a phage display library of class I lanthipeptide variants.94 A recently discovered promiscuous lanthipeptide synthetase ProcM has also been exploited to generate a large lanthipeptide plasmid-encoded libraries18 and phage display libraries.36 Our lab recently disclosed the used of the RiPP enzyme PaaA to convert adjacent glutamic acid residues into a bicyclic indolizidinone motif in mRNA display libraries (Figure 5C.3).54 These studies revealed that PaaA is broadly promiscuous outside of its glutamic acid binding epitope, suggesting that indolizidinone structures could be readily incorporated into display libraries for affinity selection purposes, and that RiPP enzymes may be broadly applicable to the diversification of GELs.
Conclusion.
GELs are inherently peptidic due to their dependence on ribosomes for synthesis. This typically limits the chemical space they can access to canonical amino acids, which in turn puts limitations on important drug properties of resulting identified ligands, such as cell permeability. Development or adaptation of several new technologies now allow for the incorporation of hundreds of new diversity elements, significantly expanding the chemical space of in vitro and in vivo GELs. Still only a fraction of the chemical potential of GELs has been tapped with these new methods. The continued investigation and optimization of orthogonal aaRSs and ribozymes, as well as the development of new GEL-compatible chemistries will continue to press the capabilities of GELs in the near term. Additionally, the application of peptide modifying enzymes, as mild, biocompatible reagents could still open new frontiers in GEL diversity. However, the need for robust quality control assays and metrics to assess modifications on such a massive molecular scale is still a key bottleneck in this development. Metrics and QC methods, like those discussed in this review will likely need to continue to evolve to meet the growing complexity of GEL libraries.
Acknowledgements.
We thank M. Bowler, J. Pelton, N. Kramer, and C. Neumann for informative discussions and feedback. This work was supported by NIH Grant GM125005 (AAB).
References
- (1).Clark MA; Acharya RA; Arico-Muendel CC; Belyanskaya SL; Benjamin DR; Carlson NR; Centrella PA; Chiu CH; Creaser SP; Cuozzo JW; et al. Design, Synthesis and Selection of DNA-Encoded Small-Molecule Libraries. Nat. Chem. Biol 2009, 5 (9), 647–654. 10.1038/nchembio.211. [DOI] [PubMed] [Google Scholar]
- (2).Wilson DS; Keefe AD; Szostak JW The Use of MRNA Display to Select High-Affinity Protein-Binding Peptides. Proc. Natl. Acad. Sci. U. S. A 2001, 98 (7), 3750–3755. 10.1073/pnas.061028198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (3).Clackson T; Hoogenboom HR; Griffiths AD; Winter G Making Antibody Fragments Using Phage Display Libraries. Nature 1991, 352, 624–628. 10.1002/047120918x.emb1111. [DOI] [PubMed] [Google Scholar]
- (4).Sohrabi C; Foster A; Tavassoli A Methods for Generating and Screening Libraries of Genetically Encoded Cyclic Peptides in Drug Discovery. Nat. Rev. Chem 2020, 4 (2), 90–101. 10.1038/s41570-019-0159-2. [DOI] [PubMed] [Google Scholar]
- (5).Smith GP; Petrenko VA Phage Display. Chem. Rev 1997, 97 (2), 391–410. 10.1021/cr960065d. [DOI] [PubMed] [Google Scholar]
- (6).Tavassoli A; Benkovic SJ Split-Intein Mediated Circular Ligation Used in the Synthesis of Cyclic Peptide Libraries in E. Coli. Nat. Protoc 2007, 2 (5), 1126–1133. 10.1038/nprot.2007.152. [DOI] [PubMed] [Google Scholar]
- (7).Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto J. ichi; Kamaura M; et al. K-Ras(G12D)-Selective Inhibitory Peptides Generated by Random Peptide T7 Phage Display Technology. Biochem. Biophys. Res. Commun 2017, 484 (3), 605–611. 10.1016/j.bbrc.2017.01.147. [DOI] [PubMed] [Google Scholar]
- (8).Tanaka Y; Hipolito CJ; Maturana AD; Ito K; Kuroda T; Higuchi T; Katoh T; Kato HE; Hattori M; Kumazaki K; et al. Structural Basis for the Drug Extrusion Mechanism by a MATE Multidrug Transporter. Nature 2013, 496 (7444), 247–251. 10.1038/nature12014. [DOI] [PubMed] [Google Scholar]
- (9).Mann AP; Scodeller P; Hussain S; Braun GB; Mölder T; Toome K; Ambasudhan R; Teesalu T; Lipton SA; Ruoslahti E Identification of a Peptide Recognizing Cerebrovascular Changes in Mouse Models of Alzheimer’s Disease. Nat. Commun 2017, 8 (1). 10.1038/s41467-017-01096-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (10).Hussain S; Joo J; Kang J; Kim B; Braun GB; She ZG; Kim D; Mann AP; Mölder T; Teesalu T; et al. Antibiotic-Loaded Nanoparticles Targeted to the Site of Infection Enhance Antibacterial Efficacy. Nat. Biomed. Eng 2018, 2 (2), 95–103. 10.1038/s41551-017-0187-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (11).Liao HI; Olson CA; Hwang S; Deng H; Wong E; Baric RS; Roberts RW; Sun R MRNA Display Design of Fibronectin-Based Intrabodies That Detect and Inhibit Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein. J. Biol. Chem 2009, 284 (26), 17512–17520. 10.1074/jbc.M901547200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (12).Kamalinia G; Engel BJ; Srinivasamani A; Grindel BJ; Ong JN; Curran MA; Takahashi TT; Millward SW; Roberts RW; Roberts RW; et al. MRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). ACS Chem. Biol 2020, 15 (6), 1630–1641. 10.1021/acschembio.0c00264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (13).Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; et al. Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX. Proc. Natl. Acad. Sci. U. S. A 2009, 106 (12), 4665–4670. 10.1073/pnas.0900947106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (14).Bertoldo D; Khan MMG; Dessen P; Held W; Huelsken J; Heinis C Phage Selection of Peptide Macrocycles against β-Catenin to Interfere with Wnt Signaling. ChemMedChem 2016, 11 (8), 834–839. 10.1002/cmdc.201500557. [DOI] [PubMed] [Google Scholar]
- (15).Young TS; Young DD; Ahmad I; Louis JM; Benkovic SJ; Schultz PG Evolution of Cyclic Peptide Protease Inhibitors. Proc. Natl. Acad. Sci. U. S. A 2011, 108 (27), 11052–11056. 10.1073/pnas.1108045108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (16).Baeriswyl V; Calzavarini S; Gerschheimer C; Diderich P; Angelillo-scherrer A; Heinis C Development of a Selective Peptide Macrocycle Inhibitor of Coagulation Factor XII toward the Generation of a Safe Antithrombotic Therapy. J. Med. Chem 2013, 56 (9), 3742–3746. 10.1021/jm400236j. [DOI] [PubMed] [Google Scholar]
- (17).Diderich P; Heinis C Phage Selection of Bicyclic Peptides Binding Her2. Tetrahedron 2014, 70 (42), 7733–7739. 10.1016/j.tet.2014.05.106. [DOI] [Google Scholar]
- (18).Yang X; Lennard KR; He C; Walker MC; Ball AT; Doigneaux C; Tavassoli A; van der Donk WA A Lanthipeptide Library Used to Identify a Protein–Protein Interaction Inhibitor. Nat. Chem. Biol 2018, 14 (4), 375–380. 10.1038/s41589-018-0008-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (19).Angelini A; Cendron L; Chen S; Touati J; Winter G; Zanotti G; Heinis C Bicyclic Peptide Inhibitor Reveals Large Contact Interface with a Protease Target. ACS Chem. Biol 2012, 7 (5), 817–821. 10.1021/cb200478t. [DOI] [PubMed] [Google Scholar]
- (20).Hayashi Y; Morimoto J; Suga H In Vitro Selection of Anti-Akt2 Thioether-Macrocyclic Peptides Leading to Isoform-Selective Inhibitors. ACS Chem. Biol 2012, 7 (3), 607–613. 10.1021/cb200388k. [DOI] [PubMed] [Google Scholar]
- (21).Kawakami T; Ishizawa T; Fujino T; Reid PC; Suga H; Murakami H In Vitro Selection of Multiple Libraries Created by Genetic Code Reprogramming to Discover Macrocyclic Peptides That Antagonize VEGFR2 Activity in Living Cells. ACS Chem. Biol 2013, 8 (6), 1205–1214. 10.1021/cb300697h. [DOI] [PubMed] [Google Scholar]
- (22).Tavassoli A; Lu Q; Gam J; Pan H; Benkovic SJ; Cohen SN Inhibition of HIV Budding by a Genetically Selected Cyclic Peptide Targeting the Gag-TSG101 Interaction. ACS Chem. Biol 2008, 3 (12), 757–764. 10.1021/cb800193n. [DOI] [PubMed] [Google Scholar]
- (23).Millward SW; Fiacco S; Austin RJ; Roberts RW Design of Cyclic Peptides That Bind Protein Surfaces with Antibody-like Affinity. ACS Chem. Biol 2007, 2 (9), 625–634. 10.1021/cb7001126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (24).Josephson K; Ricardo A; Szostak JW MRNA Display: From Basic Principles to Macrocycle Drug Discovery. Drug Discov. Today 2014, 19 (4), 388–399. 10.1016/j.drudis.2013.10.011. [DOI] [PubMed] [Google Scholar]
- (25).Omidfar K; Daneshpour M Advances in Phage Display Technology for Drug Discovery. Expert Opin. Drug Discov 2015, 10 (6), 651–669. 10.1517/17460441.2015.1037738. [DOI] [PubMed] [Google Scholar]
- (26).Liu R; Li X; Lam KS Combinatorial Chemistry in Drug Discovery. Curr. Opin. Chem. Biol 2017, 38, 117–126. 10.1016/j.cbpa.2017.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (27).Hamzeh-Mivehroud M; Alizadeh AA; Morris MB; Bret Church W; Dastmalchi S Phage Display as a Technology Delivering on the Promise of Peptide Drug Discovery. Drug Discov. Today 2013, 18 (23–24), 1144–1157. 10.1016/j.drudis.2013.09.001. [DOI] [PubMed] [Google Scholar]
- (28).Deyle K; Kong XD; Heinis C Phage Selection of Cyclic Peptides for Application in Research and Drug Development. Acc. Chem. Res 2017, 50 (8), 1866–1874. 10.1021/acs.accounts.7b00184. [DOI] [PubMed] [Google Scholar]
- (29).Tavassoli A SICLOPPS Cyclic Peptide Libraries in Drug Discovery. Curr. Opin. Chem. Biol 2017, 38, 30–35. 10.1016/j.cbpa.2017.02.016. [DOI] [PubMed] [Google Scholar]
- (30).Scott CP; Abel-Santos E; Wall M; Wahnon DC; Benkovic SJ Production of Cyclic Peptides and Proteins in Vivo. Proc. Natl. Acad. Sci. U. S. A 1999, 96 (24), 13638–13643. 10.1073/pnas.96.24.13638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (31).Horswill AR; Savinov SN; Benkovic SJ A Systematic Method for Identifying Small-Molecule Modulators of Protein-Protein Interactions. Proc. Natl. Acad. Sci. U. S. A 2004, 101 (44), 15591–15596. 10.1073/pnas.0406999101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (32).Male AL; Forafonov F; Cuda F; Zhang G; Zheng S; Oyston PCF; Chen PR; Williamson ED; Tavassoli A Targeting Bacillus Anthracis Toxicity with a Genetically Selected Inhibitor of the PA/CMG2 Protein-Protein Interaction. Sci. Rep 2017, 7 (1), 1–9. 10.1038/s41598-017-03253-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (33).Song X; Lu LY; Passioura T; Suga H Macrocyclic Peptide Inhibitors for the Protein-Protein Interaction of Zaire Ebola Virus Protein 24 and Karyopherin Alpha 5. Org. Biomol. Chem 2017, 15 (24), 5155–5160. 10.1039/c7ob00012j. [DOI] [PubMed] [Google Scholar]
- (34).Kawakami T; Ogawa K; Hatta T; Goshima N; Natsume T Directed Evolution of a Cyclized Peptoid-Peptide Chimera against a Cell-Free Expressed Protein and Proteomic Profiling of the Interacting Proteins to Create a Protein-Protein Interaction Inhibitor. ACS Chem. Biol 2016, 11 (6), 1569–1577. 10.1021/acschembio.5b01014. [DOI] [PubMed] [Google Scholar]
- (35).Owens AE; Paola I. De; Hansen WA; Liu Y; Khare SD; Fasan R Design and Evolution of a Macrocyclic Peptide Inhibitor of the Sonic Hedgehog/Patched Interaction. J. Am. Chem. Soc 2017, 139 (36), 12559–12568. 10.1021/jacs.7b06087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (36).Urban JH; Moosmeier MA; Aumüller T; Thein M; Bosma T; Rink R; Groth K; Zulley M; Siegers K; Tissot K; et al. Phage Display and Selection of Lanthipeptides on the Carboxy-Terminus of the Gene-3 Minor Coat Protein. Nat. Commun 2017, 8, 1–10. 10.1038/s41467-017-01413-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (37).Ricardo A; Arata M; Demarco S; Dhamnaskar K; Hammer R; Fridkis-hareli M; Josephson K; Parker G; Seyb K; Tang G; et al. Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Blood 2015, 126. [Google Scholar]
- (38).Mudd GE; Brown A; Chen L; van Rietschoten K; Watcham S; Teufel DP; Pavan S; Lani R; Huxley P; Bennett GS Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads. J. Med. Chem 2020, 63 (8), 4107–4116. 10.1021/acs.jmedchem.9b02129. [DOI] [PubMed] [Google Scholar]
- (39).Teufel DP; Bennett G; Harrison H; Van Rietschoten K; Pavan S; Stace C; Le Floch F; Van Bergen T; Vermassen E; Barbeaux P; et al. Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema. J. Med. Chem 2018, 61 (7), 2823–2836. 10.1021/acs.jmedchem.7b01625. [DOI] [PubMed] [Google Scholar]
- (40).Valeur E; Jimonet P New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm. J. Med. Chem 2018, 61 (20), 9004–9029. 10.1021/acs.jmedchem.8b00378. [DOI] [PubMed] [Google Scholar]
- (41).Cary DR; Ohuchi M; Reid PC; Masuya K Constrained Peptides in Drug Discovery and Development. Yuki Gosei Kagaku Kyokaishi/Journal Synth. Org. Chem 2017, 75 (11), 1171–1178. 10.5059/yukigoseikyokaishi.75.1171. [DOI] [Google Scholar]
- (42).Zorzi A; Deyle K; Heinis C Cyclic Peptide Therapeutics: Past, Present and Future. Curr. Opin. Chem. Biol 2017, 38, 24–29. 10.1016/j.cbpa.2017.02.006. [DOI] [PubMed] [Google Scholar]
- (43).Yamagishi Y; Shoji I; Miyagawa S; Kawakami T; Katoh T; Goto Y; Suga H Natural Product-like Macrocyclic N-Methyl-Peptide Inhibitors against a Ubiquitin Ligase Uncovered from a Ribosome-Expressed de Novo Library. Chem. Biol 2011, 18 (12), 1562–1570. 10.1016/j.chembiol.2011.09.013. [DOI] [PubMed] [Google Scholar]
- (44).Nitsche C; Passioura T; Varava P; Mahawaththa MC; Leuthold MM; Klein CD; Suga H; Otting G De Novo Discovery of Nonstandard Macrocyclic Peptides as Noncompetitive Inhibitors of the Zika Virus NS2B-NS3 Protease. ACS Med. Chem. Lett 2019, 10 (2), 168–174. 10.1021/acsmedchemlett.8b00535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (45).Morimoto J; Hayashi Y; Suga H Discovery of Macrocyclic Peptides Armed with a Mechanism-Based Warhead: Isoform-Selective Inhibition of Human Deacetylase SIRT2. Angew. Chemie - Int. Ed 2012, 51 (14), 3423–3427. 10.1002/anie.201108118. [DOI] [PubMed] [Google Scholar]
- (46).Howell SM; Fiacco SV; Takahashi TT; Jalali-yazdi F; Millward SW; Hu B; Wang P; Roberts RW Serum Stable Natural Peptides Designed by MRNA Display. Sci. Rep 2014, 4 (1), 6008–6012. 10.1038/srep06008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (47).Johansen-Leete J; Passioura T; Passioura T; Passioura T; Passioura T; Foster SR; Bhusal RP; Ford DJ; Liu M; Jongkees SAK; et al. Discovery of Potent Cyclic Sulfopeptide Chemokine Inhibitors via Reprogrammed Genetic Code MRNA Display. J. Am. Chem. Soc 2020, 142 (20), 9141–9146. 10.1021/jacs.0c03152. [DOI] [PubMed] [Google Scholar]
- (48).Goto Y; Katoh T; Suga H Flexizymes for Genetic Code Reprogramming. Nat. Protoc 2011, 6 (6), 779–790. 10.1038/nprot.2011.331. [DOI] [PubMed] [Google Scholar]
- (49).Liu CC; Schultz PG Adding New Chemistries to the Genetic Code. Annu. Rev. Biochem 2010, 79 (1), 413–444. 10.1146/annurev.biochem.052308.105824. [DOI] [PubMed] [Google Scholar]
- (50).Heinis C; Rutherford T; Freund S; Winter G Phage-Encoded Combinatorial Chemical Libraries Based on Bicyclic Peptides. Nat. Chem. Biol 2009, 5 (7), 502–507. 10.1038/nchembio.184. [DOI] [PubMed] [Google Scholar]
- (51).Kale SS; Villequey C; Kong X; Zorzi A; Deyle K; Heinis C Cyclization of Peptides with Two Chemical Bridges Affords Large Scaffold Diversities. Nat. Chem 2018, 10 (7), 715–723. 10.1038/s41557-018-0042-7. [DOI] [PubMed] [Google Scholar]
- (52).Hacker DE; Hoinka J; Iqbal ES; Przytycka TM; Hartman MCT Highly Constrained Bicyclic Scaffolds for the Discovery of Protease-Stable Peptides via MRNA Display. ACS Chem. Biol 2017, 12 (3), 795–804. 10.1021/acschembio.6b01006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (53).Ng S; Jafari MR; Matochko WL; Derda R Quantitative Synthesis of Genetically Encoded Glycopeptide Libraries Displayed on M13 Phage. ACS Chem. Biol 2012, 7 (9), 1482–1487. 10.1021/cb300187t. [DOI] [PubMed] [Google Scholar]
- (54).Fleming SR; Himes PM; Ghodge SV; Goto Y; Suga H; Bowers AA Exploring the Post-Translational Enzymology of PaaA by MRNA Display. J. Am. Chem. Soc 2020. 10.1021/jacs.0c01576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (55).Franzini RM; Randolph C Chemical Space of DNA-Encoded Libraries: Miniperspective. J. Med. Chem 2016, 59 (14), 6629–6644. 10.1021/acs.jmedchem.5b01874. [DOI] [PubMed] [Google Scholar]
- (56).Medina-Franco J; Martinez-Mayorga K; Giulianotti M; Houghten R; Pinilla C Visualization of the Chemical Space in Drug Discovery. Curr. Comput. Aided-Drug Des 2008, 4 (4), 322–333. 10.2174/157340908786786010. [DOI] [Google Scholar]
- (57).Castillon GA; Adames NR; Rosello CH; Seidel HS; Longtine MS; Cooper JA; Heil-Chapdelaine RA A Novel Strategy for In Vitro Selection of Peptide-Drug Conjugates. Chem. Biol 2003, 10, 233–239. 10.1016/S1074-5521(03)00047-4. [DOI] [PubMed] [Google Scholar]
- (58).Kitov PI; Vinals DF; Ng S; Tjhung KF; Derda R Rapid, Hydrolytically Stable Modification of Aldehyde-Terminated Proteins and Phage Libraries. J. Am. Chem. Soc 2014, 136 (23), 8149–8152. 10.1021/ja5023909. [DOI] [PubMed] [Google Scholar]
- (59).Triana V; Derda R Tandem Wittig/Diels-Alder Diversification of Genetically Encoded Peptide Libraries. Org. Biomol. Chem 2017, 15 (37), 7869–7877. 10.1039/c7ob01635b. [DOI] [PubMed] [Google Scholar]
- (60).Bellotto S; Chen S; Rentero Rebollo I; Wegner HA; Heinis C Phage Selection of Photoswitchable Peptide Ligands. J. Am. Chem. Soc 2014, 136 (16), 5880–5883. 10.1021/ja501861m. [DOI] [PubMed] [Google Scholar]
- (61).Rentero Rebollo I; Heinis C Phage Selection of Bicyclic Peptides. Methods 2013, 60 (1), 46–54. 10.1016/j.ymeth.2012.12.008. [DOI] [PubMed] [Google Scholar]
- (62).Stress CJ; Sauter B; Schneider LA; Sharpe T; Gillingham D A DNA-Encoded Chemical Library Incorporating Elements of Natural Macrocycles. Angew. Chemie - Int. Ed 2019, 9570–9574. 10.1002/anie.201902513. [DOI] [PubMed] [Google Scholar]
- (63).Usanov DL; Chan AI; Maianti JP; Liu DR Second-Generation DNA-Templated Macrocycle Libraries for the Discovery of Bioactive Small Molecules. Nat. Chem 2018, 10 (July). 10.1038/s41557-018-0033-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (64).Zhu Z; Shaginian A; Grady LC; Kee TO; Shi XE; Davie CP; Simpson GL; Messer A; Evindar G; Bream RN; et al. Design and Application of a DNA-Encoded Macrocyclic Peptide Library. ACS Chem. Biol 2018, 13 (1), 53–59. 10.1021/acschembio.7b00852. [DOI] [PubMed] [Google Scholar]
- (65).Over B; Matsson P; Tyrchan C; Artursson P; Doak BC; Foley MA; Hilgendorf C; Johnston SE; Lee MD; Lewis RJ; et al. Structural and Conformational Determinants of Macrocycle Cell Permeability. Nat. Chem. Biol 2016, 12 (12), 1065–1074. 10.1038/nchembio.2203. [DOI] [PubMed] [Google Scholar]
- (66).Calendar R; Berg P Purification and Physical Characterization of Tyrosyl Ribonucleic Acid Synthetases from Escherichia Coli and Bacillus Subtilis. Biochemistry 1966, 5 (5), 1681–1690. 10.1021/bi00869a033. [DOI] [PubMed] [Google Scholar]
- (67).Lee SG; Lipmann F [45] Tyrocidine Synthetase System. Methods Enzymol. 1975, 43 (C), 585–602. 10.1016/0076-6879(75)43121-4. [DOI] [PubMed] [Google Scholar]
- (68).Linne U; Marahiel MA Reactions Catalyzed by Mature and Recombinant Nonribosomal Peptide Synthetases. Methods Enzymol. 2004, 388 (2001), 293–315. 10.1016/S0076-6879(04)88024-8. [DOI] [PubMed] [Google Scholar]
- (69).Otten LG; Schaffer ML; Villiers BRM; Stachelhaus T; Hollfelder F An Optimized ATP/PPi-Exchange Assay in 96-Well Format for Screening of Adenylation Domains for Applications in Combinatorial Biosynthesis. Biotechnol. J 2007, 2 (2), 232–240. 10.1002/biot.200600220. [DOI] [PubMed] [Google Scholar]
- (70).Phelan VV; Du Y; McLean JA; Bachmann BO Adenylation Enzyme Characterization Using γ −18O4-ATP Pyrophosphate Exchange. Chem. Biol 2009, 16 (5), 473–478. 10.1016/j.chembiol.2009.04.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (71).Wolfson AD; Uhlenbeck OC Modulation of TRNAAla Identity by Inorganic Pyrophosphatase. Proc. Natl. Acad. Sci. U. S. A 2002, 99 (9), 5965–5970. 10.1073/pnas.092152799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (72).Hartman MCT; Josephson K; Szostak JW Enzymatic Aminoacylation of TRNA with Unnatural Amino Acids. Proc. Natl. Acad. Sci 2006, 103 (12), 4356–4361. 10.1073/pnas.0509219103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (73).Josephson K; Hartman MCT; Szostak JW Ribosomal Synthesis of Unnatural Peptides. J. Am. Chem. Soc 2005, 127 (33), 11727–11735. 10.1021/ja0515809. [DOI] [PubMed] [Google Scholar]
- (74).Murakami H; Ohta A; Ashigai H; Suga H A Highly Flexible TRNA Acylation Method for Non-Natural Polypeptide Synthesis. Nat. Methods 2006, 3 (5), 357–359. 10.1038/nmeth877. [DOI] [PubMed] [Google Scholar]
- (75).Kawakami T; Sasaki T; Reid PC; Murakami H Incorporation of Electrically Charged N-Alkyl Amino Acids into Ribosomally Synthesized Peptides via Post-Translational Conversion. Chem. Sci 2014, 5 (3), 887–893. 10.1039/c3sc52744a. [DOI] [Google Scholar]
- (76).Hartman MCT; Josephson K; Lin CW; Szostak JW An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides. PLoS One 2007, 2 (10). 10.1371/journal.pone.0000972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (77).White ER; Reed TM; Ma Z; Hartman MCT Replacing Amino Acids in Translation: Expanding Chemical Diversity with Non-Natural Variants. Methods 2013, 60 (1), 70–74. 10.1016/j.ymeth.2012.03.015. [DOI] [PubMed] [Google Scholar]
- (78).Tian F; Tsao ML; Schultz PG A Phage Display System with Unnatural Amino Acids. J. Am. Chem. Soc 2004, 126 (49), 15962–15963. 10.1021/ja045673m. [DOI] [PubMed] [Google Scholar]
- (79).Liu CC; Mack AV; Brustad EM; Mills JH; Groff D; Smider VV; Schultz PG Evolution of Proteins with Genetically Encoded “Chemical Warheads.” J. Am. Chem. Soc 2009, 131 (28), 9616–9617. 10.1021/ja902985e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (80).Owens AE; Iannuzzelli JA; Gu Y; Fasan R MOrPH-PhD: An Integrated Phage Display Platform for the Discovery of Functional Genetically Encoded Peptide Macrocycles. ACS Cent. Sci 2020. 10.1021/acscentsci.9b00927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (81).Wang XS; Chen PHC; Hampton JT; Tharp JM; Reed CA; Das SK; Wang DS; Hayatshahi HS; Shen Y; Liu J; et al. A Genetically Encoded, Phage-Displayed Cyclic-Peptide Library. Angew. Chemie - Int. Ed 2019, 58 (44), 15904–15909. 10.1002/anie.201908713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (82).Frost JR; Jacob NT; Papa LJ; Owens AE; Fasan R Ribosomal Synthesis of Macrocyclic Peptides in Vitro and in Vivo Mediated by Genetically Encoded Aminothiol Unnatural Amino Acids. ACS Chem. Biol 2015, 10 (8), 1805–1816. 10.1021/acschembio.5b00119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (83).Tharp JM; Hampton JT; Reed CA; Ehnbom A; Chen PHC; Morse JS; Kurra Y; Pérez LM; Xu S; Liu WR An Amber Obligate Active Site-Directed Ligand Evolution Technique for Phage Display. Nat. Commun 2020, 11 (1). 10.1038/s41467-020-15057-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (84).Kawakami T; Murakami H; Suga H Messenger RNA-Programmed Incorporation of Multiple N-Methyl-Amino Acids into Linear and Cyclic Peptides. Chem. Biol 2008, 15 (1), 32–42. 10.1016/j.chembiol.2007.12.008. [DOI] [PubMed] [Google Scholar]
- (85).Kawakami T; Ishizawa T; Murakami H Extensive Reprogramming of the Genetic Code for Genetically Encoded Synthesis of Highly N-Alkylated Polycyclic Peptidomimetics. J. Am. Chem. Soc 2013, 135 (33), 12297–12304. 10.1021/ja405044k. [DOI] [PubMed] [Google Scholar]
- (86).Santoso B; Lam S; Murray BW; Chen G A Simple and Efficient Maleimide-Based Approach for Peptide Extension with a Cysteine-Containing Peptide Phage Library. Bioorganic Med. Chem. Lett 2013, 23 (20), 5680–5683. 10.1016/j.bmcl.2013.08.032. [DOI] [PubMed] [Google Scholar]
- (87).Arai K; Tsutsumi H; Mihara H A Monosaccharide-Modified Peptide Phage Library for Screening of Ligands to Carbohydrate-Binding Proteins. Bioorganic Med. Chem. Lett 2013, 23 (17), 4940–4943. 10.1016/j.bmcl.2013.06.059. [DOI] [PubMed] [Google Scholar]
- (88).Ng S; Derda R Phage-Displayed Macrocyclic Glycopeptide Libraries. Org. Biomol. Chem 2016, 14 (24), 5539–5545. 10.1039/c5ob02646f. [DOI] [PubMed] [Google Scholar]
- (89).Scholle MD; Kriplani U; Pabon A; Sishtla K; Glucksman MJ; Kay BK Mapping Protease Substrates by Using a Biotinylated Phage Substrate Library. ChemBioChem 2006, 7 (5), 834–838. 10.1002/cbic.200500427. [DOI] [PubMed] [Google Scholar]
- (90).McCarthy KA; Kelly MA; Li K; Cambray S; Hosseini AS; Van Opijnen T; Gao J Phage Display of Dynamic Covalent Binding Motifs Enables Facile Development of Targeted Antibiotics. J. Am. Chem. Soc 2018, 140 (19), 6137–6145. 10.1021/jacs.8b02461. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (91).Jafari MR; Deng L; Kitov PI; Ng S; Matochko WL; Tjhung KF; Zeberoff A; Elias A; Klassen JS; Derda R Discovery of Light-Responsive Ligands through Screening of a Light-Responsive Genetically Encoded Library. ACS Chem. Biol 2014, 9 (2), 443–450. 10.1021/cb4006722. [DOI] [PubMed] [Google Scholar]
- (92).Navaratna T; Atangcho L; Mahajan M; Subramanian V; Case M; Min A; Tresnak D; Thurber GM Directed Evolution Using Stabilized Bacterial Peptide Display. J. Am. Chem. Soc 2020, 142 (4), 1882–1894. 10.1021/jacs.9b10716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (93).Millward SW; Takahashi TT; Roberts RW A General Route for Post-Translational Cyclization of MRNA Display Libraries. J. Am. Chem. Soc 2005, 127 (41), 14142–14143. 10.1021/ja054373h. [DOI] [PubMed] [Google Scholar]
- (94).Hetrick KJ; Walker MC; Van Der Donk WA Development and Application of Yeast and Phage Display of Diverse Lanthipeptides. ACS Cent. Sci 2018, 4 (4), 458–467. 10.1021/acscentsci.7b00581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (95).Jongkees SAK; Umemoto S; Suga H Linker-Free Incorporation of Carbohydrates into in Vitro Displayed Macrocyclic Peptides. Chem. Sci 2017, 8 (2), 1474–1481. 10.1039/C6SC04381J. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (96).Palei S; Becher KS; Nienberg C; Jose J; Mootz HD Bacterial Cell-Surface Display of Semisynthetic Cyclic Peptides. ChemBioChem 2019, 20 (1), 72–77. 10.1002/cbic.201800552. [DOI] [PubMed] [Google Scholar]
- (97).Ernst C; Sindlinger J; Schwarzer D; Koch P; Boeckler FM The Symmetric Tetravalent Sulfhydryl-Specific Linker NATBA Facilitates a Combinatorial “Tool Kit” Strategy for Phage Display-Based Selection of Functionalized Bicyclic Peptides. ACS Omega 2018, 3 (10), 12361–12368. 10.1021/acsomega.8b01814. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (98).Guillen Schlippe YV; Hartman MCT; Josephson K; Szostak JW In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors. J. Am. Chem. Soc 2012, 134 (25), 10469–10477. 10.1021/ja301017y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (99).Gram H; Schmitz R; Zuber JF; Baumann G Identification of Phosphopeptide Ligands for the Src-Homology 2 (SH2) Domain of Grb2 by Phage Display. Eur. J. Biochem 1997, 246 (3), 633–637. 10.1111/j.1432-1033.1997.00633.x. [DOI] [PubMed] [Google Scholar]
- (100).Schmitz R; Baumann G; Gram H Catalytic Specificity of Phosphotyrosine Kinases Blk, Lyn, c-Src and Syk as Assessed by Phage Display. J. Mol. Biol 1996, 260 (5), 664–677. 10.1006/jmbi.1996.0429. [DOI] [PubMed] [Google Scholar]
- (101).Tjhung KF; Kitov PI; Ng S; Kitova EN; Deng L; Klassen JS; Derda R Silent Encoding of Chemical Post-Translational Modifications in Phage-Displayed Libraries. J. Am. Chem. Soc 2016, 138 (1), 32–35. 10.1021/jacs.5b10390. [DOI] [PubMed] [Google Scholar]
- (102).Ng S; Jafari MR; Derda R Bacteriophages and Viruses as a Support for Organic Synthesis and Combinatorial Chemistry. ACS Chem. Biol 2012, 7 (1), 123–138. 10.1021/cb200342h. [DOI] [PubMed] [Google Scholar]
- (103).Fukunaga K; Hatanaka T; Ito Y; Taki M Gp10 Based-Thioetherification (10BASEd-T) on a Displaying Library Peptide of Bacteriophage T7. Mol. Biosyst 2013, 9 (12), 2988–2991. 10.1039/c3mb70379g. [DOI] [PubMed] [Google Scholar]
- (104).Tokunaga Y; Azetsu Y; Fukunaga K; Hatanaka T; Ito Y; Taki M Pharmacophore Generation from a Drug-like Core Molecule Surrounded by a Library Peptide via the 10BASEd-T on Bacteriophage T7. Molecules 2014, 19 (2), 2481–2496. 10.3390/molecules19022481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (105).Horiya S; Bailey JK; Temme JS; Guillen Schlippe YV; Krauss IJ Directed Evolution of Multivalent Glycopeptides Tightly Recognized by HIV Antibody 2G12. J. Am. Chem. Soc 2014, 136 (14), 5407–5415. 10.1021/ja500678v. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (106).Chen S; Rentero Rebollo I; Buth SA; Morales-Sanfrutos J; Touati J; Leiman PG; Heinis C Bicyclic Peptide Ligands Pulled out of Cysteine-Rich Peptide Libraries. J. Am. Chem. Soc 2013, 135 (17), 6562–6569. 10.1021/ja400461h. [DOI] [PubMed] [Google Scholar]
- (107).Dwyer MA; Lu W; Dwyer JJ; Kossiakoff AA Biosynthetic Phage Display: A Novel Protein Engineering Tool Combining Chemical and Genetic Diversity. Chem. Biol 2000, 7 (4), 263–274. 10.1016/S1074-5521(00)00102-2. [DOI] [PubMed] [Google Scholar]
- (108).Matochko WL; Derda R Error Analysis of Deep Sequencing of Phage Libraries: Peptides Censored in Sequencing. Comput. Math. Methods Med 2013, 2013. 10.1155/2013/491612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (109).Zade HM; Keshavarz R; Shekarabi HSZ; Bakhshinejad B Biased Selection of Propagation-Related TUPs from Phage Display Peptide Libraries. Amino Acids 2017, 49 (8), 1293–1308. 10.1007/s00726-017-2452-z. [DOI] [PubMed] [Google Scholar]
- (110).He B; Tjhung KF; Bennett NJ; Chou Y; Rau A; Huang J; Derda R Compositional Bias in Naïve and Chemically-Modified Phage-Displayed Libraries Uncovered by Paired-End Deep Sequencing. Sci. Rep 2018, 8 (1), 1–14. 10.1038/s41598-018-19439-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (111).Derda R; Tang SKY; Whitesides GM Uniform Amplification of Phage with Different Growth Characteristics in Individual Compartments Consisting of Monodisperse Droplets. Angew. Chemie - Int. Ed 2010, 49 (31), 5301–5304. 10.1002/anie.201001143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (112).Fukunaga K; Taki M Practical Tips for Construction of Custom Peptide Libraries and Affinity Selection by Using Commercially Available Phage Display Cloning Systems. J. Nucleic Acids 2012, 2012. 10.1155/2012/295719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (113).Paschke M Phage Display Systems and Their Applications. Appl. Microbiol. Biotechnol 2006, 70 (1), 2–11. 10.1007/s00253-005-0270-9. [DOI] [PubMed] [Google Scholar]
- (114).Passioura T; Katoh T; Goto Y; Suga H Selection-Based Discovery of Druglike Macrocyclic Peptides. Annu. Rev. Biochem 2014, 83 (1), 727–752. 10.1146/annurev-biochem-060713-035456. [DOI] [PubMed] [Google Scholar]
- (115).Li S; Millward S; Roberts R In Vitro Selection of MRNA Display Libraries Containing an Unnatural Amino Acid. J. Am. Chem. Soc 2002, 124 (34), 9972–9973. 10.1021/ja026789q. [DOI] [PubMed] [Google Scholar]
- (116).Frankel A; Roberts RW In Vitro Selection for Sense Codon Suppression. Rna 2003, 9 (7), 780–786. 10.1261/rna.5350303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (117).Liu M; Tada S; Ito M; Abe H; Ito Y In Vitro Selection of a Photo-Responsive Peptide Aptamer Using Ribosome Display. Chem. Commun 2012, 48 (97), 11871–11873. 10.1039/c2cc36618e. [DOI] [PubMed] [Google Scholar]
- (118).Wang W; Uzawa T; Tochio N; Hamatsu J; Hirano Y; Tada S; Saneyoshi H; Kigawa T; Hayashi N; Ito Y; et al. A Fluorogenic Peptide Probe Developed by in Vitro Selection Using TRNA Carrying a Fluorogenic Amino Acid. Chem. Commun 2014, 50 (22), 2962–2964. 10.1039/C3CC47624C. [DOI] [PubMed] [Google Scholar]
- (119).Manandhar Y; Bahadur KCT; Wang W; Uzawa T; Aigaki T; Ito Y In Vitro Selection of a Peptide Aptamer That Changes Fluorescence in Response to Verotoxin. Biotechnol. Lett 2015, 37 (3), 619–625. 10.1007/s10529-014-1719-7. [DOI] [PubMed] [Google Scholar]
- (120).Wang W; Hirano Y; Uzawa T; Liu M; Taiji M; Ito Y In Vitro Selection of a Peptide Aptamer That Potentiates Inhibition of Cyclin-Dependent Kinase 2 by Purvalanol. Medchemcomm 2014, 5 (9), 1400–1403. 10.1039/c4md00142g. [DOI] [Google Scholar]
- (121).Tara Bahadur KC; Tada S; Zhu L; Uzawa T; Minagawa N; Luo SC; Zhao H; Yu HH; Aigaki T; Ito Y In Vitro Selection of Electrochemical Peptide Probes Using Bioorthogonal TRNA for Influenza Virus Detection. Chem. Commun 2018, 54 (41), 5201–5204. 10.1039/c8cc01775a. [DOI] [PubMed] [Google Scholar]
- (122).Merryman C; Green R Transformation of Aminoacyl TRNAs for the In Vitro Selection of “Drug-like” Molecules. Chem. Biol 2004, 11 (4), 575–582. 10.1016/j.chembiol.2004.03.009. [DOI] [PubMed] [Google Scholar]
- (123).Subtelny AO; Hartman MCT; Szostak JW Ribosomal Synthesis of N-Methyl Peptides. J. Am. Chem. Soc 2008, 130 (19), 6131–6136. 10.1021/ja710016v. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (124).Fahnestock S; Rich A Ribosome-Catalyzed Polyester Formation. Science (80-. ). 1971, 173 (3994), 340–343. 10.1126/science.173.3994.340. [DOI] [PubMed] [Google Scholar]
- (125).Forster AC; Tan Z; Nalam MNL; Lin H; Qu H; Cornish VW; Blacklow SC Programming Peptidomimetic Syntheses by Translating Genetic Codes Designed de Novo. Proc. Natl. Acad. Sci 2003, 100 (11), 6353–6357. 10.1073/pnas.1132122100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (126).Forster AC; Cornish VW; Blacklow SC Pure Translation Display. Anal. Biochem 2004, 333 (2), 358–364. 10.1016/j.ab.2004.06.028. [DOI] [PubMed] [Google Scholar]
- (127).Iqbal ES; Dods KK; Hartman MCT Ribosomal Incorporation of Backbone Modified Amino Acids: Via an Editing-Deficient Aminoacyl-TRNA Synthetase. Org. Biomol. Chem 2018, 16 (7), 1073–1078. 10.1039/c7ob02931d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (128).Iqbal ES; Richardson SL; Abrigo NA; Dods KK; Osorio Franco HE; Gerrish HS; Kotapati HK; Morgan IM; Masterson DS; Hartman MCT A New Strategy for the in Vitro Selection of Stapled Peptide Inhibitors by MRNA Display. Chem. Commun 2019, 55 (61), 8959–8962. 10.1039/c8cc10192b. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (129).Murakami H; Saito H; Suga H A Versatile TRNA Aminoacylation Catalyst Based on RNA. Chem. Biol 2003, 10 (7), 655–662. 10.1016/S1074-5521(03)00145-5. [DOI] [PubMed] [Google Scholar]
- (130).Xiao H; Murakami H; Suga H; Ferré-D’Amaré AR Structural Basis of Specific TRNA Aminoacylation by a Small in Vitro Selected Ribozyme. Nature 2008, 454 (7202), 358–361. 10.1038/nature07033. [DOI] [PubMed] [Google Scholar]
- (131).Niwa N; Yamagishi Y; Murakami H; Suga H A Flexizyme That Selectively Charges Amino Acids Activated by a Water-Friendly Leaving Group. Bioorg. Med. Chem. Lett 2009, 19 (14), 3892–3894. 10.1016/j.bmcl.2009.03.114. [DOI] [PubMed] [Google Scholar]
- (132).Goto Y; Ohta A; Sako Y; Yamagishi Y; Murakami H; Suga H Reprogramming the Translation Initiation for the Synthesis of Physiologically Stable Cyclic Peptides. ACS Chem. Biol 2008, 3 (2), 120–129. 10.1021/cb700233t. [DOI] [PubMed] [Google Scholar]
- (133).Goto Y; Murakami H; Suga H Initiating Translation with D-Amino Acids. RNA 2008, 14 (7), 1390–1398. 10.1261/rna.1020708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (134).Yin Y; Ochi N; Craven TW; Baker D; Takigawa N; Suga H De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor. J. Am. Chem. Soc 2019, 141 (49), 19193–19197. 10.1021/jacs.9b09106. [DOI] [PubMed] [Google Scholar]
- (135).Takatsuji R; Shinbara K; Katoh T; Goto Y; Passioura T; Yajima R; Komatsu Y; Suga H Ribosomal Synthesis of Backbone-Cyclic Peptides Compatible with in Vitro Display. J. Am. Chem. Soc 2019. 10.1021/jacs.8b05327. [DOI] [PubMed] [Google Scholar]
- (136).Ohshiro Y; Nakajima E; Goto Y; Fuse S; Takahashi T; Doi T; Suga H Ribosomal Synthesis of Backbone-Macrocyclic Peptides Containing γ-Amino Acids. ChemBioChem 2011, 12 (8), 1183–1187. 10.1002/cbic.201100104. [DOI] [PubMed] [Google Scholar]
- (137).Rogers JM; Kwon S; Dawson SJ; Mandal PK; Suga H; Huc I Ribosomal Synthesis and Folding of Peptide-Helical Aromatic Foldamer Hybrids. Nat. Chem 2018, 10 (4), 405–412. 10.1038/s41557-018-0007-x. [DOI] [PubMed] [Google Scholar]
- (138).Lee J; Schwieter KE; Watkins AM; Kim DS; Yu H; Schwarz KJ; Lim J; Coronado J; Byrom M; Anslyn EV; et al. Expanding the Limits of the Second Genetic Code with Ribozymes. Nat. Commun 2019, 10 (1), 1–12. 10.1038/s41467-019-12916-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (139).Ad O; Hoffman KS; Cairns AG; Featherston AL; Miller SJ; Söll D; Schepartz A Translation of Diverse Aramid- And 1,3-Dicarbonyl-Peptides by Wild Type Ribosomes in Vitro. ACS Cent. Sci 2019, 5 (7), 1289–1294. 10.1021/acscentsci.9b00460. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (140).Hipolito C; Tanaka Y; Katoh T; Nureki O; Suga H A Macrocyclic Peptide That Serves as a Cocrystallization Ligand and Inhibits the Function of a MATE Family Transporter. Molecules 2013, 18 (9), 10514–10530. 10.3390/molecules180910514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (141).Katoh T; Suga H Ribosomal Elongation of Cyclic γ-Amino Acids Using a Reprogrammed Genetic Code. J. Am. Chem. Soc 2020, 142 (11), 4965–4969. 10.1021/jacs.9b12280. [DOI] [PubMed] [Google Scholar]
- (142).Kawakami T; Murakami H; Suga H Ribosomal Synthesis of Polypeptoids and Peptoid–Peptide Hybrids. J. Am. Chem. Soc 2008, 130 (50), 16861–16863. 10.1021/ja806998v. [DOI] [PubMed] [Google Scholar]
- (143).Iwane Y; Hitomi A; Murakami H; Katoh T; Goto Y; Suga H Expanding the Amino Acid Repertoire of Ribosomal Polypeptide Synthesis via the Artificial Division of Codon Boxes. Nat. Chem 2016, 8 (4), 317–325. 10.1038/nchem.2446. [DOI] [PubMed] [Google Scholar]
- (144).Iwasaki K; Goto Y; Katoh T; Yamashita T; Kaneko S; Suga H A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM. J. Mol. Evol 2015, 81 (5–6), 210–217. 10.1007/s00239-015-9710-z. [DOI] [PubMed] [Google Scholar]
- (145).Sakai K; Passioura T; Sato H; Ito K; Furuhashi H; Umitsu M; Takagi J; Kato Y; Mukai H; Warashina S; et al. Macrocyclic Peptide-Based Inhibition and Imaging of Hepatocyte Growth Factor. Nat. Chem. Biol 2019, 15 (6), 598–606. 10.1038/s41589-019-0285-7. [DOI] [PubMed] [Google Scholar]
- (146).Nawatha M; Rogers JM; Bonn SM; Livneh I; Lemma B; Mali SM; Vamisetti GB; Sun H; Bercovich B; Huang Y; et al. De Novo Macrocyclic Peptides That Specifically Modulate Lys48-Linked Ubiquitin Chains. Nat. Chem 2019, 11 (7), 644–652. 10.1038/s41557-019-0278-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (147).Passioura T; Liu W; Dunkelmann D; Higuchi T; Suga H Display Selection of Exotic Macrocyclic Peptides Expressed under a Radically Reprogrammed 23 Amino Acid Genetic Code. J. Am. Chem. Soc 2018, 140 (37), 11551–11555. 10.1021/jacs.8b03367. [DOI] [PubMed] [Google Scholar]
- (148).Iwasaki K; Goto Y; Katoh T; Suga H Selective Thioether Macrocyclization of Peptides Having the N-Terminal 2-Chloroacetyl Group and Competing Two or Three Cysteine Residues in Translation. Org. Biomol. Chem 2012, 10 (30), 5783–5786. 10.1039/c2ob25306b. [DOI] [PubMed] [Google Scholar]
- (149).Sako Y; Goto Y; Murakami H; Suga H Ribosomal Synthesis of Peptidase-Resistant Peptides Closed by a Nonreducible Inter-Side-Chain Bond. ACS Chem. Biol 2008, 3 (4), 241–249. 10.1021/cb800010p. [DOI] [PubMed] [Google Scholar]
- (150).Sako Y; Morimoto J; Murakami H; Suga H Ribosomal Synthesis of Bicyclic Peptides via Two Orthogonal Inter-Side-Chain Reactions. J. Am. Chem. Soc 2008, 130 (23), 7232–7234. 10.1021/ja800953c. [DOI] [PubMed] [Google Scholar]
- (151).Bashiruddin NK; Nagano M; Suga H Synthesis of Fused Tricyclic Peptides Using a Reprogrammed Translation System and Chemical Modification. Bioorg. Chem 2015, 61, 45–50. 10.1016/j.bioorg.2015.06.002. [DOI] [PubMed] [Google Scholar]
- (152).Yamagshi Y; Ahigai H; Goto Y; Murakami H; Suga H Ribosomal Synthesis of Cyclic Peptides with a Fluorogenic Oxidative Coupling Reaction. ChemBioChem 2009, 10 (9), 1469–1472. 10.1002/cbic.200900021. [DOI] [PubMed] [Google Scholar]
- (153).Fujino T; Goto Y; Suga H; Murakami H Reevaluation of the D-Amino Acid Compatibility with the Elongation Event in Translation. J. Am. Chem. Soc 2013, 135 (5), 1830–1837. 10.1021/ja309570x. [DOI] [PubMed] [Google Scholar]
- (154).Katoh T; Iwane Y; Suga H Logical Engineering of D-Arm and T-Stem of TRNA That Enhances D-Amino Acid Incorporation. Nucleic Acids Res. 2017, 45 (22), 12601–12610. 10.1093/nar/gkx1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (155).Katoh T; Tajima K; Suga H Consecutive Elongation of D-Amino Acids in Translation. Cell Chem. Biol 2017, 24 (1), 46–54. 10.1016/j.chembiol.2016.11.012. [DOI] [PubMed] [Google Scholar]
- (156).Fujino T; Goto Y; Suga H; Murakami H Ribosomal Synthesis of Peptides with Multiple β-Amino Acids. J. Am. Chem. Soc 2016, 138 (6), 1962–1969. 10.1021/jacs.5b12482. [DOI] [PubMed] [Google Scholar]
- (157).Katoh T; Sengoku T; Hirata K; Ogata K; Suga H Ribosomal Synthesis and de Novo Discovery of Bioactive Foldamer Peptides Containing Cyclic β-Amino Acids. Nat. Chem 2020. 10.1038/s41557-020-0525-1. [DOI] [PubMed] [Google Scholar]
- (158).Katoh T; Suga H Ribosomal Incorporation of Consecutive β-Amino Acids. J. Am. Chem. Soc 2018, 140 (38), 12159–12167. 10.1021/jacs.8b07247. [DOI] [PubMed] [Google Scholar]
- (159).Ohta A; Murakami H; Higashimura E; Suga H Synthesis of Polyester by Means of Genetic Code Reprogramming. Chem. Biol 2007, 14 (12), 1315–1322. 10.1016/j.chembiol.2007.10.015. [DOI] [PubMed] [Google Scholar]
- (160).Cervettini D; Tang S; Fried SD; Willis JCW; Funke LFH; Colwell LJ; Chin JW Rapid Discovery and Evolution of Orthogonal Aminoacyl-TRNA Synthetase–TRNA Pairs. Nat. Biotechnol 2020. 10.1038/s41587-020-0479-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (161).Wang L; Magliery TJ; Liu DR; Schultz PG A New Functional Suppressor TRNA/Aminoacyl-TRNA Synthetase Pair for the in Vivo Incorporation of Unnatural Amino Acids into Proteins [16]. J. Am. Chem. Soc 2000, 122 (20), 5010–5011. 10.1021/ja000595y. [DOI] [Google Scholar]
- (162).Wan W; Tharp JM; Liu WR Pyrrolysyl-TRNA Synthetase: An Ordinary Enzyme but an Outstanding Genetic Code Expansion Tool. Biochim. Biophys. Acta - Proteins Proteomics 2014, 1844 (6), 1059–1070. 10.1016/j.bbapap.2014.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (163).Dumas A; Lercher L; Spicer CD; Davis BG Designing Logical Codon Reassignment – Expanding the Chemistry in Biology. Chem. Sci 2015, 6 (1), 50–69. 10.1039/C4SC01534G. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (164).Vargas-Rodriguez O; Sevostyanova A; Söll D; Crnković A Upgrading Aminoacyl-TRNA Synthetases for Genetic Code Expansion. Curr. Opin. Chem. Biol 2018, 46, 115–122. 10.1016/j.cbpa.2018.07.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (165).Lee YJ; Wu B; Raymond JE; Zeng Y; Fang X; Wooley KL; Liu WR A Genetically Encoded Acrylamide Functionality. ACS Chem. Biol 2013, 8 (8), 1664–1670. 10.1021/cb400267m. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (166).Chin JW; Martin AB; King DS; Wang L; Schultz PG Addition of a Photocrosslinking Amino Acid to the Genetic Code of Escherichia Coli. Proc. Natl. Acad. Sci. U. S. A 2002, 99 (17), 11020–11024. 10.1073/pnas.172226299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (167).Frost JR; Wu Z; Lam YC; Owens AE; Fasan R Side-Chain-to-Tail Cyclization of Ribosomally Derived Peptides Promoted by Aryl and Alkyl Amino-Functionalized Unnatural Amino Acids. Org. Biomol. Chem 2016, 14 (24), 5803–5812. 10.1039/c6ob00192k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (168).Bionda N; Fasan R Ribosomal Synthesis of Natural-Product-Like Bicyclic Peptides in Escherichia Coli. ChemBioChem 2015, 16 (14), 2011–2016. 10.1002/cbic.201500179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (169).Bionda N; Cryan AL; Fasan R Bioinspired Strategy for the Ribosomal Synthesis of Thioether-Bridged Macrocyclic Peptides in Bacteria. ACS Chem. Biol 2014, 9 (9), 2008–2013. 10.1021/cb500311k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (170).Wang L; Brock A; Herberich B; Schultz PG Expanding the Genetic Code of Escherichia Coli. Science (80-. ). 2001, 292 (5516), 498–500. 10.1126/science.1060077. [DOI] [PubMed] [Google Scholar]
- (171).Chin JW; Santoro SW; Martin AB; King DS; Wang L; Schultz PG Addition of p -Azido- l -Phenylalanine to the Genetic Code of Escherichia c Oli. J. Am. Chem. Soc 2002, 124 (31), 9026–9027. 10.1021/ja027007w. [DOI] [PubMed] [Google Scholar]
- (172).Wang L; Zhang Z; Brock A; Schultz PG Addition of the Keto Functional Group to the Genetic Code of Escherichia Coli. Proc. Natl. Acad. Sci 2003, 100 (1), 56–61. 10.1073/pnas.0234824100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (173).Wang L; Brock A; Schultz PG Adding l</Scp> −3-(2-Naphthyl)Alanine to the Genetic Code of E. Coli. J. Am. Chem. Soc 2002, 124 (9), 1836–1837. 10.1021/ja012307j. [DOI] [PubMed] [Google Scholar]
- (174).Liu CC; Schultz PG Recombinant Expression of Selectively Sulfated Proteins in Escherichia Coli. Nat. Biotechnol 2006, 24 (11), 1436–1440. 10.1038/nbt1254. [DOI] [PubMed] [Google Scholar]
- (175).Xie J; Liu W; Schultz PG A Genetically Encoded Bidentate, Metal-Binding Amino Acid. Angew. Chemie - Int. Ed 2007, 46 (48), 9239–9242. 10.1002/anie.200703397. [DOI] [PubMed] [Google Scholar]
- (176).Brustad E; Bushey ML; Lee JW; Groff D; Liu W; Schultz PG A Genetically Encoded Boronate-Containing Amino Acid. Angew. Chemie - Int. Ed 2008, 47 (43), 8220–8223. 10.1002/anie.200803240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (177).Liu CC; Mack AV; Tsao ML; Mills JH; Hyun SL; Choe H; Farzan M; Schultz PG; Smider VV Protein Evolution with an Expanded Genetic Code. Proc. Natl. Acad. Sci. U. S. A 2008, 105 (46), 17688–17693. 10.1073/pnas.0809543105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (178).Rondot S; Koch J; Breitling F; Dübel S A Helper Phage to Improve Single-Chain Antibody Presentation in Phage Display. Nat. Biotechnol 2001, 19 (1), 75–78. 10.1038/83567. [DOI] [PubMed] [Google Scholar]
- (179).Kang M; Light K; Ai HW; Shen W; Kim CH; Chen PR; Lee HS; Solomon EI; Schultz PG Evolution of Iron(II)-Finger Peptides by Using a Bipyridyl Amino Acid. ChemBioChem 2014, 15 (6), 822–825. 10.1002/cbic.201300727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (180).Hohsaka T; Ashizuka Y; Murakami H; Sisido M Incorporation of Nonnatural Amino Acids into Streptavidin through In Vitro Frame-Shift Suppression. J. Am. Chem. Soc 1996, 118 (40), 9778–9779. 10.1021/ja9614225. [DOI] [Google Scholar]
- (181).Hohsaka T; Kajihara D; Ashizuka Y; Murakami H; Sisido M Efficient Incorporation of Nonnatural Amino Acids with Large Aromatic Groups into Streptavidin in in Vitro Protein Synthesizing Systems. J. Am. Chem. Soc 1999, 121 (1), 34–40. 10.1021/ja9813109. [DOI] [Google Scholar]
- (182).Hohsaka T; Ashizuka Y; Taira H; Murakami H; Sisido M Incorporation of Nonnatural Amino Acids into Proteins by Using Various Four-Base Codons in an Escherichia Coli in Vitro Translation System. Biochemistry 2001, 40 (37), 11060–11064. 10.1021/bi0108204. [DOI] [PubMed] [Google Scholar]
- (183).Muranaka N; Hohsaka T; Sisido M Four-Base Codon Mediated MRNA Display to Construct Peptide Libraries That Contain Multiple Nonnatural Amino Acids. Nucleic Acids Res. 2006, 34 (1). 10.1093/nar/gnj003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (184).Oller-Salvia B; Chin JW Efficient Phage Display with Multiple Distinct Non-Canonical Amino Acids Using Orthogonal Ribosome-Mediated Genetic Code Expansion. Angew. Chemie Int. Ed 2019, 58 (32), 10844–10848. 10.1002/anie.201902658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (185).Malone ML; Paegel BM What Is a “DNA-Compatible” Reaction? ACS Comb. Sci 2016, 18 (4), 182–187. 10.1021/acscombsci.5b00198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (186).Wang J; Lundberg H; Asai S; Martín-Acosta P; Chen JS; Brown S; Farrell W; Dushin RG; O’Donnell CJ; Ratnayake AS; et al. Kinetically Guided Radical-Based Synthesis of C(Sp 3 )−C(Sp 3 ) Linkages on DNA. Proc. Natl. Acad. Sci 2018, 115 (28), E6404–E6410. 10.1073/pnas.1806900115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (187).Gunnoo SB; Madder A Chemical Protein Modification through Cysteine. ChemBioChem 2016, 17, 529–553. 10.1002/cbic.201500667. [DOI] [PubMed] [Google Scholar]
- (188).Boutureira O; Bernardes GJL Advances in Chemical Protein Modification. Chem. Rev 2015, 115 (5), 2174–2195. 10.1021/cr500399p. [DOI] [PubMed] [Google Scholar]
- (189).Baslé E; Joubert N; Pucheault M Protein Chemical Modification on Endogenous Amino Acids. Chem. Biol 2010, 17 (3), 213–227. 10.1016/j.chembiol.2010.02.008. [DOI] [PubMed] [Google Scholar]
- (190).Jin X; Newton JR; Montgomery-Smith S; Smith GP A Generalized Kinetic Model for Amine Modification of Proteins with Application to Phage Display. Biotechniques 2009, 46 (3), 175–182. 10.2144/000113074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (191).Li K; Chen Y; Li S; Nguyen HG; Niu Z; You S; Mello CM; Lu X; Wang Q Chemical Modification of M13 Bacteriophage and Its Application in Cancer Cell Imaging. Bioconjug. Chem 2010, 21 (7), 1369–1377. 10.1021/bc900405q. [DOI] [PubMed] [Google Scholar]
- (192).Bernard JML; Francis MB Chemical Strategies for the Covalent Modification of Filamentous Phage. Front. Microbiol 2014, 5 (DEC), 1–7. 10.3389/fmicb.2014.00734. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (193).Carrico ZM; Farkas ME; Zhou Y; Hsiao SC; Marks JD; Chokhawala H; Clark DS; Francis MB N-Terminal Labeling of Filamentous Phage to Create Cancer Marker Imaging Agents. ACS Nano 2012, 6 (8), 6675–6680. 10.1021/nn301134z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (194).Yacoby I; Shamis M; Bar H; Shabat D; Benhar I Targeting Antibacterial Agents by Using Drug-Carrying Filamentous Bacteriophages. Antimicrob. Agents Chemother 2006, 50 (6), 2087–2097. 10.1128/AAC.00169-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (195).Yacoby I; Bar H; Benhar I Targeted Drug-Carrying Bacteriophages as Antibacterial Nanomedicines. Antimicrob. Agents Chemother 2007, 51 (6), 2156–2163. 10.1128/AAC.00163-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (196).Vaks L; Benhar I In Vivo Characteristics of Targeted Drug-Carrying Filamentous Bacteriophage Nanomedicines. J. Nanobiotechnology 2011, 9, 1–10. 10.1186/1477-3155-9-58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (197).Jespers L; Bonnert TP; Winter G Selection of Optical Biosensors from Chemisynthetic Antibody Libraries. Protein Eng. Des. Sel 2004, 17 (10), 709–713. 10.1093/protein/gzh083. [DOI] [PubMed] [Google Scholar]
- (198).Kather I; Bippes CA; Schmid FX A Stable Disulfide-Free Gene-3-Protein of Phage Fd Generated by in Vitro Evolution. J. Mol. Biol 2005, 354 (3), 666–678. 10.1016/j.jmb.2005.09.086. [DOI] [PubMed] [Google Scholar]
- (199).Sojitra M; Sarkar S; Maghera J; Rodrigues E; Carpenter E; Seth S; Vinals DF; Bennett N; Reddy R; Khalil A; et al. Genetically Encoded, Multivalent Liquid Glycan Array (LiGA). 2020. 10.1101/2020.03.24.997536. [DOI] [PMC free article] [PubMed]
- (200).Abel GR; Calabrese ZA; Ayco J; Hein JE; Ye T Measuring and Suppressing the Oxidative Damage to DNA during Cu(I)-Catalyzed Azide-Alkyne Cycloaddition. Bioconjug. Chem 2016, 27 (3), 698–704. 10.1021/acs.bioconjchem.5b00665. [DOI] [PubMed] [Google Scholar]
- (201).Li S; Cai H; He J; Chen H; Lam S; Cai T; Zhu Z; Bark SJ; Cai C Extent of the Oxidative Side Reactions to Peptides and Proteins during the CuAAC Reaction. Bioconjug. Chem 2016, 27 (10), 2315–2322. 10.1021/acs.bioconjchem.6b00267. [DOI] [PubMed] [Google Scholar]
- (202).Hong V; Presolski SI; Ma C; Finn MG Analysis and Optimization of Copper-Catalyzed Azide-Alkyne Cycloaddition for Bioconjugation. Angew. Chemie - Int. Ed 2009, 48 (52), 9879–9883. 10.1002/anie.200905087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (203).Urquhart T; Daub E; Honek JF Bioorthogonal Modification of the Major Sheath Protein of Bacteriophage M13: Extending the Versatility of Bionanomaterial Scaffolds. Bioconjug. Chem 2016, 27 (10), 2276–2280. 10.1021/acs.bioconjchem.6b00460. [DOI] [PubMed] [Google Scholar]
- (204).Hofmann FT; Szostak JW; Seebeck FP In Vitro Selection of Functional Lantipeptides. J. Am. Chem. Soc 2012, 134 (19), 8038–8041. 10.1021/ja302082d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (205).Ng S; Lin E; Kitov PI; Tjhung KF; Gerlits OO; Deng L; Kasper B; Sood A; Paschal BM; Zhang P; et al. Genetically Encoded Fragment-Based Discovery of Glycopeptide Ligands for Carbohydrate-Binding Proteins. J. Am. Chem. Soc 2015, 137 (16), 5248–5251. 10.1021/ja511237n. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (206).Ng S; Bennett NJ; Schulze J; Gao N; Rademacher C; Derda R Genetically-Encoded Fragment-Based Discovery of Glycopeptide Ligands for DC-SIGN. Bioorg. Med. Chem 2018, 26 (19), 5368–5377. 10.1016/j.bmc.2018.08.036. [DOI] [PubMed] [Google Scholar]
- (207).Vinals DF; Kitov PI; Tu Z; Zou C; Cairo CW; Lin HC-H; Derda R Selection of Galectin-3 Ligands Derived from Genetically Encoded Glycopeptide Libraries. Pept. Sci 2019, 111 (1), e24097. [Google Scholar]
- (208).Li K; Wang W; Gao J Fast and Stable N-Terminal Cysteine Modification through Thiazolidino Boronate Mediated Acyl Transfer. Angew. Chemie - Int. Ed 2020, 59 (34), 14246–14250. 10.1002/anie.202000837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (209).Garbe D; Thiel IV; Mootz HD Protein Trans-Splicing on an M13 Bacteriophage: Towards Directed Evolution of a Semisynthetic Split Intein by Phage Display. J. Pept. Sci 2010, 16 (10), 575–581. 10.1002/psc.1243. [DOI] [PubMed] [Google Scholar]
- (210).White ER; Sun L; Ma Z; Beckta JM; Danzig BA; Hacker DE; Huie M; Williams DC; Edwards RA; Valerie K; et al. Peptide Library Approach to Uncover Phosphomimetic Inhibitors of the BRCA1 C-Terminal Domain. ACS Chem. Biol 2015, 10 (5), 1198–1208. 10.1021/cb500757u. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (211).Ekanayake A; Sobze L; Youk J; Bennett NJ; Mukherjee R; Bhardwaj A; Wuest F; Derda R Genetically Encoded Fragment-Based Discovery (GE-FBD) from Phage-Displayed Macrocyclic Libraries with Genetically-Encoded Unnatural Pharmacophores. 10.26434/chemrxiv.12644225.v1. [DOI] [PubMed]
- (212).Bacon K; Blain A; Burroughs M; McArthrur N; Rao BM; Menegatti S Isolation of Chemically Cyclized Peptide Binders Using Yeast Surface Display. ACS Comb. Sci 2020. 10.1021/acscombsci.0c00076. [DOI] [PubMed] [Google Scholar]
- (213).Zheng X; Li Z; Gao W; Meng X; Li X; Luk LYP; Zhao Y; Tsai YH; Wu C Condensation of 2-((Alkylthio)(Aryl)Methylene)Malononitrile with 1,2-Aminothiol as a Novel Bioorthogonal Reaction for Site-Specific Protein Modification and Peptide Cyclization. J. Am. Chem. Soc 2020, 142 (11), 5097–5103. 10.1021/jacs.9b11875. [DOI] [PubMed] [Google Scholar]
- (214).Diderich P; Bertoldo D; Dessen P; Khan MM; Pizzitola I; Held W; Huelsken J; Heinis C Phage Selection of Chemically Stabilized α-Helical Peptide Ligands. ACS Chem. Biol 2016, 11 (5), 1422–1427. 10.1021/acschembio.5b00963. [DOI] [PubMed] [Google Scholar]
- (215).Jafari MR; Lakusta J; Lundgren RJ; Derda R Allene Functionalized Azobenzene Linker Enables Rapid and Light-Responsive Peptide Macrocyclization. Bioconjug. Chem 2016, 27 (3), 509–514. 10.1021/acs.bioconjchem.6b00026. [DOI] [PubMed] [Google Scholar]
- (216).Kong XD; Moriya J; Carle V; Pojer F; Abriata LA; Deyle K; Heinis C De Novo Development of Proteolytically Resistant Therapeutic Peptides for Oral Administration. Nat. Biomed. Eng 2020, 4 (5), 560–571. 10.1038/s41551-020-0556-3. [DOI] [PubMed] [Google Scholar]
- (217).Sugimura Y; Yokoyama K; Nio N; Maki M; Hitomi K Identification of Preferred Substrate Sequences of Microbial Transglutaminase from Streptomyces Mobaraensis Using a Phage-Displayed Peptide Library. Arch. Biochem. Biophys 2008, 477 (2), 379–383. 10.1016/j.abb.2008.06.014. [DOI] [PubMed] [Google Scholar]
- (218).Chen I; Choi Y-A; Ting AY Phage Display Evolution of a Peptide Substrate for Yeast Biotin Ligase and Application to Two-Color Quantum Dot Labeling of Cell Surface Proteins. J. Am. Chem. Soc 2007, 129 (20), 6619–6625. 10.1021/ja071013g. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (219).Sunbul M; Marshall NJ; Zou Y; Zhang K; Yin J Catalytic Turnover-Based Phage Selection for Engineering the Substrate Specificity of Sfp Phosphopantetheinyl Transferase. J. Mol. Biol 2009, 387 (4), 883–898. 10.1016/j.jmb.2009.02.010. [DOI] [PubMed] [Google Scholar]
- (220).Sunbul M; Emerson N; Yin J Enzyme-Catalyzed Substrate Attachment to Phage Surfaces for the Selection of Catalytic Activities. ChemBioChem 2011, 12 (3), 380–386. 10.1002/cbic.201000475. [DOI] [PubMed] [Google Scholar]
- (221).Çelik E; Fisher AC; Guarino C; Mansell TJ; DeLisa MP A Filamentous Phage Display System for N-Linked Glycoproteins. Protein Sci. 2010, 19 (10), 2006–2013. 10.1002/pro.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (222).Kretz CA; Dai M; Soylemez O; Yee A; Desch KC; Siemieniak D; Tomberg K; Kondrashov FA; Meng F; Ginsburg D Massively Parallel Enzyme Kinetics Reveals the Substrate Recognition Landscape of the Metalloprotease ADAMTS13. Proc. Natl. Acad. Sci. U. S. A 2015, 112 (30), 9328–9333. 10.1073/pnas.1511328112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (223).Matthews DJ; Wells JA Substrate Phage : Selection of Protease Substrates by Monovalent Phage Display. Science (80-. ). 1993, 260 (5111), 1113–1117. [DOI] [PubMed] [Google Scholar]
- (224).Teschke T; Geltinger B; Dose A; Freund C; Schwarzer D Probing the Recognition of Post-Translational Modifications by Combining Sortase-Mediated Ligation and Phage-Assisted Selection. ACS Chem. Biol 2013, 8 (8), 1692–1697. 10.1021/cb4001487. [DOI] [PubMed] [Google Scholar]
- (225).Hess GT; Cragnolini JJ; Popp MW; Allen MA; Dougan SK; Spooner E; Ploegh HL; Belcher AM; Guimaraes CP M13 Bacteriophage Display Framework That Allows Sortase-Mediated Modification of Surface-Accessible Phage Proteins. Bioconjug. Chem 2012, 23 (7), 1478–1487. 10.1021/bc300130z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (226).Bosma T; Kuipers A; Bulten E; de Vries L; Rink R; Moll GN Bacterial Display and Screening of Posttranslationally Thioether-Stabilized Peptides. Appl. Environ. Microbiol 2011, 77 (19), 6794–6801. 10.1128/AEM.05550-11. [DOI] [PMC free article] [PubMed] [Google Scholar]